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ABSTRACT
The field of cost-effectiveness analysis (CEA) deals with the comparison of health
interventions based on both costs and effectiveness (ability to improve health). This
dissertation makes several methodological contributions to this area.
Part I develops direct methods for computing mean costs and effectiveness, and
hence conducting CEA, in multi-state disease processes. The common approach
in this case is to use discrete-event simulation techniques to simulate the process
to get the associated cost and effectiveness outcomes. However, the setting up and
implementation of simulation studies can be time and resource intensive. The disser-
tation develops analytical expressions for the time-to-failure, reward processes, and
their (discounted) expectations for time-homogeneous semi-Markov processes with
progressive structure. Direct Monte Carlo methods are proposed for time-varying
multi-state processes. The advantages of these direct methods over discrete-event
simulation are discussed. Sensitivity analysis to parameter estimation is also consid-
ered. The results are demonstrated on illustrative applications.
Part II deals proposes a richer analysis of cost-effectiveness data from discrete
event simulation of disease processes. Such simulations generate extensive amounts
of data which are rarely examined in detail. The analysis is typically reduced to com-
puting and comparing simple CEA metrics. This part of the dissertation proposes a
comprehensive exploratory analysis of the data through graphical techniques. This
includes examining both cross-sectional and temporal views of the time-to-failure,
x
cost, and effectiveness distributions. The concept of a treatment-effect function is
discussed, and it leads to generalized versions of two common CEA metrics. The
potential for richer analysis is illustrated through various examples.
Part III of the dissertation reviews the common CEA metrics based on means
of the cost and effectiveness outcomes and discusses comparisons based on first and
second-order stochastic dominance as well as utility functions. It also deals with
methods for incorporating statistical uncertainty from estimating the unknown pa-
rameters in CEA. Large-sample normal approximations and resampling methods are
reviewed. New contributions to the CEA literature include stochastic dominance
comparisons in the presence of estimation uncertainty, use of rank methods, and
analysis with censored data.
xi
CHAPTER I
Introduction
1.1 Overview of Cost-Effectiveness Analysis
There is growing emphasis in the health care area on containing costs while also
improving effectiveness (health). This is the main goal of cost-effectiveness analysis
(CEA) which uses metrics based on costs and effectiveness to assess and compare
interventions. Cost-effectiveness analysis involves a comparison of two or more treat-
ments for health policy or medical decision making. One or more new interventions
are compared against the current or baseline intervention.
CEA was introduced to clinicians in the healthcare literature by Weinstein and
Stason (1977). Since that time, it has been widely adopted. Standards for CEA
studies were agreed upon in 1996 by the Panel of Cost-Effectiveness in Health and
Medicine (Gold et al., 1996). These standards include elements to be included in
measuring costs and effectiveness, methods of determining health and effectiveness,
and incorporating time preference and the discounting of costs and effects.
There is a large literature on the development and use of various metrics for
CEA. Most of them are based on the means of the (random) cost and effectiveness
outcomes, where the expected values are taken with respect to some population of
subjects of interest. The metric recommended for CEA in (Gold et al., 1996) is the
1
2incremental cost-effectiveness ratio (ICER). The ICER for comparing two treatments
0 and 1 is given by
(1.1) µICER =
µ1(C)− µ0(C)
µ1(E)− µ0(E) =
∆(C)
∆(E)
,
where µj(C) and µj(E) are the average cost and effectiveness measures (per person)
of the j−th intervention. Treatment 0 is typically the baseline treatment representing
the current standard of practice while 1 is a new treatment under consideration. The
decision rule associated with ICER is as follows: let λ be the amount of money that
society is willing to pay for a single unit of effectiveness. If the ICER is less than λ,
then the treatment is deemed cost-effective. If not, society would not be willing to
pay for that treatment, and it is not considered cost-effective.
Two other common metrics which are equivalent to each other are the net health
benefit (NHB) and the net monetary benefit (NMB). NHB was introduced by Stin-
nett and Mullahy (1998). NHB converts costs to effectiveness units using the willingness-
to-pay ratio as the conversion factor, and adds the incremental costs (now in effec-
tiveness units) to incremental effectiveness to get an overall benefit in effectiveness
units. Similarly, NMB converts effectiveness to cost units before calculating overall
benefit. The expression for NMB is
(1.2) µNMB(λ) = λ(µ1(E)− µ0(E))− (µ1(C)− µ0(C)) = λ∆(E)−∆(C).
The NMB and NHB, while in different units, are equivalent. Positive values of either
denote a cost-effective intervention. Otherwise, the treatment is not cost-effective.
The ICER and NMB depend on the average costs and effectiveness for the (new)
treatment being considered and the baseline treatment over the lifetime of the analy-
sis. Cost is measured in currency, and typically includes all direct costs of treatment
such as the cost of tests, drugs, supplies, doctors, nurses, other health personnel, and
3medical facilities (Gold et al., 1996). Cost may also include direct non-healthcare
costs such as transportation costs to treatment, or costs due to a change in diet.
The effectiveness of a treatment can be measured in different ways, including deaths
averted or postponed, infections averted, extended life, and quality-adjusted-life-
years (QALYs). QALYs are the most commonly used effectiveness measure in CEA
and are obtained by weighting the length of life by appropriate weights which are
supposed to measure ‘quality of life’ in the patient’s health state. The weight is
between 0 and 1, with the value of 1 referring to perfect health.
Per the recommendation in Gold et al. (1996), both costs and QALYs are dis-
counted at some rate to bring the values at different times to a common reference
value. Discounting cost is standard in the fields of economics and financial evalua-
tion. Discounting QALYs is a bit less intuitive, but CEA relies on the assumption
that QALYs have a monetary value, and also that there is a constant trade-off be-
tween costs and QALYs. Failure to discount QALYs while discounting cost results
in the Keeler-Cretin paradox, in which any treatment program’s cost-effectiveness is
improved by postponement (Keeler and Cretin, 1983).
Beyond being an academic pursuit, CEA has important uses in health policy
around the globe. The UK, Australia, and Canada require economic evaluations
before approving new healthcare technologies (Birch and Gafni, 2004; Hill et al.,
2000; Hjelmgren et al., 2001). These are countries with government-run health-
care systems, so a government-imposed limit on the cost-effectiveness of proposed
treatments is natural. Even the United States government has expressed support
for cost-effectiveness and comparative effectiveness research, in spite of the United
States’ decentralized medical insurance and payment system, with a broad base of
legislation having been introduced in Congress supporting such research (Jacob-
4son, 2007). The World Health Organization (WHO) has also developed guidelines
for the use of cost-effectiveness analysis, with particular concern on providing cost-
effectiveness information when there are limits to the time or resources that can be
invested in a study (Murray et al., 2000). Thus, there is a broad base of support
for conducting CEA studies. Additionally, there is considerable value for patients,
physicians, and policy-makers in understanding the cost, quality of life, and length
of life tradeoffs inherent in medical decisions.
In spite of the large literature that exists for CEA, there remain methodological
gaps and challenges in estimating cost-effectiveness and quantifying the uncertainty
in those estimates. Some of these gaps result from a misunderstanding of statistical
issues, due to the fact that as a relatively new and interdisciplinary field, the CEA
literature has only recently received the attention of statisticians and operations
researchers. Other gaps exist because the field of medical decision-making itself is
evolving; for instance, there have recently been calls in the literature to move beyond
simple decision analysis for the full population to decision analysis more tailored to
individual patients or groups of patients (Basu, 2009; Hayward et al., 2010; Zaric,
2003; Sculpher, 2008).
1.1.1 Methods of Conducting CEA
Two of the main challenges in CEA are obtaining the correct data for the anal-
ysis, and using that data to make meaningful inference and conclusions on cost-
effectiveness. This dissertation will focus on the latter issue, but the source and
quantity of data affects the inferential and modeling techniques available. So in
this section, we will discuss the methods of conducting CEA, and the data sources
available.
The first source of data is actual studies. Those studies may be clinical trials
5or observational studies, but are generally longitudinal. The field data from these
studies can be used to estimate ICER, NMB, and other cost-effectiveness metrics.
See, for example, Meenan et al. (1998), van Hout et al. (1994), and Kinlay et al.
(1996). However, longitudinal studies are expensive to conduct, and it takes several
months or even years for the data to become available. Another obvious limitation of
these clinical studies, related to the cost, is that they are generally of limited sample
size. This may make it more difficult to reach a conclusion on cost-effectiveness, or
even just effectiveness, than it would be with a larger sample size. In particular, it
may be difficult to identify different effects in heterogeneous groups of people.
With the limitations on clinical data, CEA is also performed by creating models
using data from may different sources. These models may be solved for expected
value, either using analytical techniques or discrete event simulation. The limitations
of this approach are the need to assume a model structure and the assumption that
extrapolations of the existing data from studies are valid.
This dissertation will address issues found in both clinical studies and simulated
studies. Two of the issues addressed relate to simulation models for CEA. The first
issue is in computing mean statistics from cost-effectiveness models in simple manner;
CEA has come to rely on discrete event simulation to generate mean values without
considering whether there are tractable analytical solutions. The second broad issue
is the use of simulation data, if simulation is used to evaluate the model. The time
and computational effort invested in discrete event simulation leads to a question
of whether and how simulation data can be used to provide individual and policy-
level decision-makers with useful information for making decisions. The third issue
addressed in this dissertation is decision-making and inference with small sample
sizes, and is more applicable in the case of clinical data.
61.2 Research Objectives and Organization of the Dissertation
The goal of this research is to improve the process of making a decision between
alternative medical treatments by improving the calculation, characterization, and
understanding of differences between them. This goal is accomplished through three
different research objectives.
1. Develop computationally simple methods for evaluating the mean cost and ef-
fectiveness for disease processes than can be modeled as multi-state processes;
2. Demonstrate the usefulness of graphical methods for analyzing data generated
from discrete event simulation more extensively and, and developing key insights
into the performance of the treatments and their comparisons;
3. Review and improve upon the literature about incorporating uncertainty into
CEA and introduce ideas about evaluating the full distribution of CEA outputs
under uncertainty, using utility theory and stochastic dominance.
The first two objectives enhance the understanding of multi-state models used in
CEA. The third objective, due to its focus on inference, is more applicable in situa-
tions of limited sample sizes, so it is more applicable in the case of conducting CEA
alongside a clinical trial or other medical observational study. As a result, the dis-
sertation can be conceptualized as containing two parts, one focused on multi-state
models and the other focused on inference. Chapters II, and III, form the first part,
and Chapter IV forms the second part. Chapters II, III, and IV have all been written
up as individual papers. As each paper is self-contained, there is some repetition in
motivation and notation between them.
71.2.1 Multi-State Models for CEA
Models of disease processes are common in the CEA literature. Markov models
for medical decision-making were proposed as an alternative to traditional decision-
analytic models for understanding medical prognosis by Beck and Pauker (1983).
Beck and Pauker (1983) used Markov multi-state models to calculate, via both ana-
lytical and simulation methods, the life expectancy of patients as a result of medical
decisions. The Markov multi-state model is a specific instance of a more general
class of multi-state models. CEA is possible in the context of multi-state models of
disease by assigning cost and effectiveness variables to states and transitions within
the disease model. In this way, CEA models are specialized examples of reward pro-
cesses in the operations research and applied probability literature (see, for example,
Howard (1971), Janssen and Manca (2006), and Janssen and Manca (2007)). In the
case of CEA models, the rewards are cost and effectiveness, as well as measures such
as NMB that are functions of the cost and effectiveness rewards. Markov models are
popular due to the relative simplicity of inference, but other modeling assumptions
are possible. One possible modeling assumption for multi-state models instead of a
Markov assumption is a semi-Markov assumption. Semi-Markov CEA models are
also present in the literature (Matchar et al., 1997; Castelli et al., 2007), although
they are considerably less common than Markov models.
Consider, as a broad example of multi-state modeling, Figure 2.1. Each state in
the model represents a distinct health state, and state K+1 is the end of the disease
process. The end of the process is the same as “failure” in the reliability literature,
and is often death, although models exist where K + 1 could have an alternative
meaning, including disease cure. Figure 2.1 shows the case only of progressively
worsening diseases, as return to a previous state is not possible. Depending on the
8Figure 1.1: Progressive Multi-state Models. Top: Single-step Bottom: Multi-step.
disease and the definition of the state-space, transitions to previous states may be
possible. The top panel is a special case where the subject can move only from a
state to its immediate right. This is useful in studying some health situations where
the disease progresses in a monotone manner. The multi-state model structure in
bottom panel of Figure 2.1 is considerably more general.
Regardless of modeling assumptions, in multi-state models of disease, the patient
is in some health state at the beginning of the study, spends an additional random of
time in that state, and then moves to another health state according to some transi-
tion probability. The subject spends a random amount of time in that state, moves
to a different state, and the process repeats until the person reaches an absorbing
state.
Even in the case of disease models with the Markov assumption, a common method
for evaluating models in the literature is discrete event simulation (DES). The basic
idea in DES is to simulate some large number of ‘patients’ through a disease process,
9with patient health states chosen randomly according to the underlying stochastic
model. This simulation process creates a stochastic disease process and reward pro-
cess for each patient. In traditional CEA, when only the sample means are used
to calculate the µICER and µNMB, this information is not used, and the simulation
may be computationally expensive or difficult to setup. Chapters II and III address
the two sides of the issue, with Chapter II focused on easier ways to evaluate multi-
state CEA disease models, and Chapter III on using the detailed information from
a traditional DES.
Chapter II presents methods for obtaining the estimates of the means of cost-
effectiveness studies modeled as progressive multi-state models. The assumption of
a progressive model is less limiting than it may seem, because with the creation
of additional states, nearly any medical process can be modeled as a progressive
process. Particular attention is given to the case where disease progression of both
the intervention being studied and the baseline population can be modeled as semi-
Markov models. Solutions for each random reward R and expected reward E(R)
for each patient are derived in the case of reward discounting and the case where
rewards are not discounted. The solution methods may be calculated analytically in
the case of stationary disease models, or models of disease in which the parameters
defining the underlying stochastic disease process does not change with time, which
is possible for acute diseases. The methods are extended to a simple and direct
simulation of sojourn time random variables and attached rewards in the case of
time-varying disease processes.
Chapter III demonstrates the usefulness graphical methods for analyzing simula-
tion data more extensively. A simulation of an arbitrarily large number of patients
generates rich data on the entire distribution of patient outcomes, with differences
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due to a combination of random chance and observable covariates. The simulation
also allows the process to be considered as a stochastic process that evolves over
time, rather than as a stochastic outcome observed at just one time, which is the
standard for CEA. As an example, instead of the summary measures Cj and Ej
(where j represents the treatment, and is taken to be 0 or 1 in this dissertation) in
traditional CEA there are cumulative reward processes Cj(t) and Ej(t). Across many
patients, these processes have a distribution at any time t, and the way the quan-
tiles of those distributions, Qj(u; t;C) and Qj(u; t;E), respectively, evolve over time
can be explored using graphical techniques. This chapter uses probability density
plots and Q-Q plots as starting points for analysis, shows several types of follow-up
analysis, and discusses the conclusions a decision-maker could reach in the context
of illustrative examples.
1.2.2 Inference for Stochastic Cost-Effectiveness with Limited Sample Size
As noted earlier, determination of cost-effectiveness is sometimes made with data
collected directly from a clinical setting. CEA measures, including ICER and NMB
must be estimated from data, and the sample size from which to make inference is
generally small. The existing CEA literature contains a large discussion about sta-
tistical inference for CEA, with a focus on determining confidence intervals for ÎCER
and N̂MB. There have been several approaches in the literature to the problem of
inference, and they are reviewed in Chapter IV. Included in this review is a discus-
sion of methodological limitations and corrections of errors in the current literature.
We also propose the application of rank-based methods to CEA.
The large-sample methods and rank-based methods are for inference about a sin-
gle point of a distribution; decision-makers with non-risk-neutral utility functions
should use information on the full range of CEA outputs. Utility functions can
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be used to map from the distribution of outputs in CEA to proper utilities in the
decision-theoretic sense of von Neumann and Morgenstern (Von Neumann and Mor-
genstern, 1947). In general, risk preference is modeled by some utility function u(x),
where each random variable xi is used as the argument is an output of CEA such
as QALY, monetary cost, or monetary benefit (for the i-th intervention). A util-
ity function, u(x) specifies the form of a decision-maker’s preference to values of an
output x; a rational decision-maker will make the choice that maximizes E(u(x)).
We demonstrate sensitivity analysis and the creation of preference regions for CEA
metrics, with a focus on the summary measure of monetary benefit.
In CEA (and in general), it is difficult to ascertain a decision-maker’s exact utility
function. If some general information about the utility function is known, however,
it can be used. For example, if the decision-maker’s utility function for NMB is
known to be of the form u(x) = − exp(−cx), but the value of c is unknown, sensi-
tivity analysis on the parameter c is possible for determining preference regions. If
even less is known about the utility function, stochastic dominance can be used to
determine which option is the best for an entire class of utility functions. For exam-
ple, if it is known that the utility function is monotonically increasing and concave
(i.e., the decision-maker is risk-averse), then the presence of second-order stochastic
dominance indicates the preferred option for all utility functions in that class. If
the utility function is restricted even less, to only the class of monotonically increas-
ing utility functions (i.e., the risk-preference of the decision-maker is unknown), then
first-order stochastic dominance of one option over the others would indicate the pre-
ferred decision. There are very few studies in CEA using stochastic dominance, and
all have considered the population distributions to be known, rather than sampled.
Chapter IV contributes to the literature by assuming that distributions are esti-
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mated, and by extending stochastic dominance inferential techniques and statistical
tests into CEA and discussing the implications for decision-makers. It also addresses
questions of utility functions and sensitivity analysis relative to utility functions.
CHAPTER II
Cost-Effectiveness Analysis in Health Policy Decision
Making: Direct Approaches for Progressive Multi-State
Models
2.1 Introduction
The field of cost-effectiveness analysis (CEA) deals with the comparison of health
interventions based on both relative costs and effectiveness (ability to improve health).
The interventions being compared may be pharmaceutical treatments, diagnostic
tools, surgical treatments, etc. CEA combines the effectiveness of a treatment and
cost with the willingness of society to pay for health into a hybrid measure of cost-
effectiveness.
Most metrics in CEA are based on the means or expected values of costs and
effectiveness outcomes. Perhaps the most common one is the incremental cost-
effectiveness ratio (ICER):
(2.1) µICER =
µ1(C)− µ0(C)
µ1(E)− µ0(E)
where µj(C) and µj(E) are the average cost and effectiveness measures (per person)
of the j−th intervention, j = 0, 1. Here intervention 0 is the standard or baseline and
intervention 1 is the new treatment being considered. The decision rule associated
with ICER is as follows. Let λ be the amount of money that society is willing to
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pay for a single unit of effectiveness. If the ICER is less than the willingness-to-pay
ratio λ, then the new treatment is deemed cost-effective. If not, it is deemed to be
not cost-effective.
A second metric that is also common is the net monetary benefit (NMB). It uses
the value of λ explicitly in determining cost effectiveness through the expression
(2.2) µNMB(λ) = λ(µ1(E)− µ0(E))− (µ1(C)− µ0(C)).
Specifically, λ is used to convert effectiveness into its monetary equivalent. If NMB
will be positive, treatment 1 is cost-effective; otherwise, it is not.
The emphasis on averages or expected values arises from economic considerations.
For example, average costs per person translates directly to the total cost of imple-
menting a medical or health intervention policy (Briggs and Gray, 1998; Thompson
and Barber, 2000; O’Hagan and Stevens, 2002). Cost is measured in currency and
typically includes all direct costs of treatment such as the cost of tests, drugs, sup-
plies, doctors, nurses, other health personnel, and medical facilities (Gold et al.,
1996). Direct non-healthcare costs such as transportation costs to get treatment or
costs due to a change in diet may also be included.
The effectiveness of a treatment can be measured in different ways: deaths averted
or postponed, infections averted, extended life, and quality-adjusted-life-years
(QALYs). QALYs are the most commonly used measure in CEA and are obtained
by weighting the lifetime in different states by appropriate weights which are sup-
posed to measure ‘quality of life’ in that health state. QALYs will be used as the
unit of effectiveness in this paper, and we will refer to QALYs and effectiveness
interchangeably.
It is common in CEA to discount both costs and QALYs at some rate to bring the
figures at different times to a common reference value. Discounting cost is standard
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in the fields of economics and finance. Discounting QALYs is less intuitive, but CEA
relies on the assumption that QALYs have a monetary value and that there is a
constant trade-off between costs and QALYs. Failure to discount QALYs while dis-
counting cost results in the Keeler-Cretin paradox, in which any treatment program’s
cost-effectiveness is improved by postponement (Keeler and Cretin, 1983).
If the two treatments are compared in longitudinal clinical trials, one can use the
field data to estimate ICER, NMB, and other cost-effectiveness metrics. See, for
example, Meenan et al. (1998), van Hout et al. (1994), and Kinlay et al. (1996).
However, longitudinal studies are expensive to conduct, and it takes several months
or even years for the data to become available. Also, potential new interventions may
just be contemplated and not actually implemented in a field study. In such cases, one
might be interested in conducting multi-scenario analyses about the new intervention,
including possible components to include, dosage levels, etc. To accommodate these
and other needs, researchers have turned to modeling and simulation techniques, and
a particularly useful tool is discrete event simulation (DES).
There are different ways of conducting DES, even within the context of CEA. Re-
gardless of the approach, the basic idea is to simulate some large number of ‘patients’
through a disease process, with patients’ health states chosen randomly according
to the underlying stochastic model (see, for example, Sonnenberg and Beck (1993)
for a discrete-time Markov model). The multi-state framework is a general way to
do this. In this set-up, the subject is in some health state at the beginning of the
study, spends an additional random of time in that state, and then moves to another
health state according to some transition probability. The subject again spends a
random amount of time in the new state, moves to a different state, and the pro-
cess repeats until the person reaches an absorbing state (failure). The multi-state
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process depends on unknown parameters including the transition probabilities, the
distributions of state occupancy times, also known as sojourn times, and parameters
associated with the effect of (patient) covariates. All of the unknown parameters have
to be estimated, usually from past studies. Sometimes these estimates come from a
longitudinal study of some relevant population of patients (Castelli et al., 2007; Gar-
diner et al., 2006). It is more likely that the data come from disparate cross-sectional
studies. Examples include Valenstein et al. (2001), Paltiel et al. (2001), Liew (2006),
Rosen et al. (2005), and Matchar et al. (2005).
Many software packages are available for conducting DES. If the multi-state model
is built as a decision tree, the software TreeAge may be used (Pauker and Wong,
2005); an example of this is the model by Rosen et al. (2005). Other modelers
may build their own simulations, using traditional programming languages. The
development and implementation of DES for CEA can be time consuming with most
real applications. One important issue in this context is that the low-probability
paths in the multi-state models may not be sampled even with large simulation
samples. Such paths may have unusually high or low rewards (costs or QALYs),
so the resulting simulation may lead to higher variability in the estimates of cost-
effectiveness metrics. (These issues are discussed in more detail in Section 2.6.2.)
The goal of this paper is to develop direct methods and, when possible, analytical
expressions for mean costs and effectiveness and hence cost-effectiveness analysis.
We restrict attention to ‘progressive’ processes (to be defined in the next section)
to simplify the problem but the results can be extended to the more general case.
There are very few papers in the CEA literature that deal with direct approaches to
calculating the mean costs and QALYs associated with patient or policy treatment
decisions. Some discussion is available in the operations research and applied prob-
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ability literature in the general context of rewards (see, for example, Janssen and
Manca (2006) and Janssen and Manca (2007)).
Analytical expressions are developed under a semi-Markov framework for the sta-
tionary case. This includes the Markov model as a special case. Direct Monte Carlo
methods are described for the cases where either or both of the sojourn time dis-
tributions and transition probabilities are non-stationary. These direct approaches
have many advantages over discrete event simulation. The benefits of analytical
expressions is clear. One does not have to conduct a simulation study, and sensi-
tivity analysis to estimating the parameters in the model can be done rather easily.
Even in cases where direct Monte Carlo simulation is used, the simulation effort is
considerably less than in setting up a DES study. Further, the simulation approach
here samples all possible paths through the multi-state process, weights the results
according to the probability, and computes the overall mean cost or effectiveness.
In DES, on the other hand, the probability of a path being sampled depends on its
probability, so some paths will have a very low probability of being included.
The rest of the paper is organized as follows. In Section 2.2, we discuss progres-
sive multi-state processes with the semi-Markov property. In Sections 2.3 and 2.4
we develop expressions for the lifetime distributions, and the random and expected
rewards earned in stationary progressive multi-state semi-Markov models of single
patients, and illustrate the methods with small examples. In Section 2.5 we discuss
combining patient-level results to achieve population-level results. We then discuss
extensions of the method to non-stationary processes and disease processes with mul-
tiple causes of death in Section 2.6. Section 2.6.2 compares the methods developed in
this paper to more traditional discrete event simulation methods, and discusses the
advantages of the methods in this paper, specifically in the context of the extensions
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Figure 2.1: Progressive Multi-state Models
Top panel: Single-step. Bottom panel: Multi-step.
proposed. Finally, we present an application to illustrate the concepts in this paper
in Section 2.7.
2.2 Progressive Multi-state Processes
We will consider the progressive multi-state processes in Figure (2.1). The top
panel is a special case where the subject can move only from a state to its immediate
right (called single-step). This is useful in studying some health situations where
the disease progresses in a straightforward manner. An illustrative application using
renal disease is discussed in Section 2.3.3. The bottom panel shows a more general
case (multi-step) where the patients can move multiple steps with each transition. As
an example of this case, a model of cardiovascular disease is discussed in Section 2.4.3.
Let {Y (t), t ∈ T } denote the state of the subject at time t for t ∈ T . Time
t can be discrete in which case T is the set of non-negative integers {0, 1, 2, ...} or
continuous in which case T is the non-negative half-line {t ≥ 0}. The process {Y (t)}
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takes values in the finite state space E = {1, 2, . . . , (K + 1)}. We take (K + 1) to be
an absorbing state or end point of the process, denoted as ‘failure.’ In the context
of CEA applications, this state will typically be death. Throughout this paper, we
assume that the states are ordered in some natural way and that the subject moves
from left to right only. This is quite natural in health settings. Cases where a patient
is ill and then recovers can be handled by adding a new state rather than allowing
the patient to return to the initial healthy state. Even though this increases the
number of states, it is useful to distinguish a patient who had been in a non-healthy
state and has not had health problems for some time from someone who has always
been healthy.
The first part of the paper deals with homogeneous multi-state processes. We will
be especially interested in semi-Markov processes (SMPs), which are generalizations
of Markov processes. It is convenient to define an SMP in terms of its equivalent
Markov renewal process (MRP) {(Jn, Tn), n = 1, 2, ...} (Janssen and Manca, 2006).
The MRP spends a random amount of time in a state i ∈ E and then jumps to
another state j ∈ E. Jn represents the state the process is in before the nth jump, and
Xn is the occupancy time in state Jn before the nth jump. Further, Tn = X1+· · ·+Xn
is the time of the nth jump. The transition probabilities and sojourn times are given
as follows:
1. the transition probability pi,j(t) = P (Jn+1 = j|Jn = i, Tn = t)
2. the state occupancy (sojourn) distributions are given by the conditional distri-
butions Fi,j(t1, t2) = P (Tn+1 ≤ t2|Tn = t1, Jn = i, Jn+1 = j).
The term Qi,j(t1, t2) = Fi,j(t1, t2)pi,j(t1) is called the semi-Markov kernel. Note
that limt1→∞Qi,j(t1, t2) = pi,j(t1). The corresponding SMP Y (t) can be obtained as
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Y (t) = Jn for t ∈ (Tn−1, Tn). For a time-homogeneous SMP, pi,j(t) is constant in
time and Fi,j(t1, t2) = P (Tn+1 ≤ t2|Tn = t1, Jn = i, Jn+1 = j) does not depend on
t1, the time of the n−th jump. The time-homogeneous Markov case is the simplest
and most well known example of a multi-state model. In this case, the sojourn
distributions Fi,j = Fi and are exponential.
2.3 Single-Step Progressive: Stationary Case
This section develops analytical expressions for the lifetime distribution and ran-
dom and expected rewards for the one-step progressive stationary (time-homogeneous)
case (top panel of Figure (2.1)). The results are developed for a single subject who
is in state s (with s ≤ K) at the start of the study and has spent a period time u in
that state. The results will be combined later to get expressions for a distribution
(population) of subjects. Note that in this one-step case, the transition probability
from state g to g + 1 is one.
2.3.1 Life Time Distribution
Let Xs,s+1(u) be the conditional random variable [Xs,s+1|Xs,s+1 ≥ u]. Then, we
can write T (s;u), the (residual) lifetime of this subject, as a sum of Xs,s+1(u) and
the subsequent Xg,g+1’s:
(2.3) T (s;u) = Xs,s+1(u) +Xs+1,s+2 + ...+XK,K+1.
Recall that the conditional distribution of Xs,s+1(u) is the same as that the uncon-
ditional distribution of Xs,s+1 in the exponential case. The special case where the
subject enters state 1 at the beginning of the study (u = 0) is obtained by taking
s = 1 and u = 0 in the above expression.
Let µs,s+1(u) = E(Xs,s+1) and µg,g+1 = E(Xg,g+1) for g > s. Then, the mean
E[T (s, u)] = µs,s+1(u) +
∑K
g=s+1 µg,g+1. For an SMP, the Xg,g+1’s are independent,
21
so the variance is also the sum of the individual variances. For the more general
stationary case (i.e., not an SMP), we have to specify the dependence structure
among the Xg,g+1’s in order to compute the variance.
Special Cases:
Case 1: Consider the Markov case where Fi,j = Fi and are exponential with mean ηi
for i = 1, ..., K. Then, Xs,s+1(u) has the same distribution as the unconditional ran-
dom variableXs,s+1. The distribution of T (s;u) is a sum of independent exponentials.
This is sometimes called a hypo-exponential distribution (Ross, 2003). The mean is∑K
i=s ηi and the variance is
∑K
i=s η
2
i . In the special case where ηi = η, i = 1, ..., K,
T (s;u) has a gamma distribution with parameters (K − s+ 1, η).
Case 2: Suppose we have a semi-Markov process where Fi,j is Gamma(κi,j, η), so the
scale parameter η is the same. Then,
∑K
g=s+1 Xg,g+1 is Z ∼Gamma(
∑K
g=s+1 κg,g+1, η),
so T (s;u) has the same distribution as Xs,s+1(u)+Z where Xs,s+1(u) is a conditional
Gamma(κs,s+1, η) random variable, conditioned on being ≥ u. If u = 0, then the
distribution is Gamma(
∑K
g=s κg,g+1, η). A similar structure holds whenever the sum
of Xg,g+1’s is closed under convolution (the sum belongs to the same family as the
original distribution) or more generally, the sum has a closed form expression. Other
distributions with this property include the Normal (although this is not usually
used to model sojourn times which are positive), Inverse Gaussian with a constraint
on the two parameters, and Poisson. However, for many of the common lifetime
distributions, such as Weibull and Lognormal, the distribution of the sum does not
have a closed form expression even when the components are independent. However,
it is relatively easy to simulate these random variables directly and obtain a Monte
Carlo approximation to the distribution of the sum in equation (2.3).
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2.3.2 Reward Random Variables and Expected Rewards
This section develops expressions for the random rewards and their expectations
accrued over a lifetime. The term ‘rewards’ represent both costs and effectiveness.
The results are obtained under the following setup:
1. There is a fixed reward Ui,j associated with transitioning from state i to state
j. This could, for example, be the cost associated with a one-time treatment;
2. There is a variable reward Vi per unit time associated with the amount of time
spent in state i. This could, for example, be the QALYs for that state (sojourn
time weighted by quality index) or some treatment cost that depends on the
amount of time spent in the state.
No discounting
Consider first the case with no discounting of rewards. Again, the subject is in
state s at the beginning of the study and has already spent an amount of time u in
that state. The total undiscounted random reward is simply
(2.4)
R(s;u) = VsXs,s+1(u) +Us,s+1 + Vs+1Xs+1,s+2 +Us+1,s+2 + ...+ VKXK,K+1 +UK,K+1.
It can be written in a compact form as
(2.5) R(s;u) =
K∑
g=s
Ug,g+1 + VsXs,s+1(u) +
K∑
g=s+1
VgXg,g+1.
Let µg,g+1 be defined as before as the expectation of Xg,g+1. Then, the expected
reward is
(2.6) E(R(s;u)) =
K∑
g=s
Ug,g+1 + Vsµs,s+1(u) +
K∑
g=s+1
Vgµg,g+1.
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The variance of R(s, u) can also be computed from equation (2.5). In the case of
an SMP where the Xg,g+1’s are independent, the variance is also just the sum of the
variances:
V ar(R(s;u)) = V 2s σ
2
s,s+1(u) +
K∑
g=s+1
V 2g σ
2
g,g+1,
where σ2s,s+1(u) = V ar(Xs,s+1(u)) and σ
2
g,g+1 = V ar(Xg,g+1).
The more interesting problem is to compute the reward random variable and its
moments under discounting.
Discounting
For discrete time, the rewards are discounted by a discount rate r for each unit of
time. Throughout, let θ = 1
(1+r)
, so θ has the simple effect of discounting the reward
by a single time unit. For continuous time, the discount rate is ρ, so the discount
factor for a time of length x is exp(−ρx).
Define
(2.7) Wg,g+1 = Ug,g+1 + α(Vg+1 − Vg)
with α = θ
(1−θ) for discrete time and α = 1/ρ for continuous time. Further, in the
discrete time case, the discount factor Zs,s+1 = θ
Xs,s+1(u) and Zg,g+1 = θ
Xg,g+1 for
g ≥ s + 1. In the continuous time case, Zs,s+1 = exp(−ρXs,s+1(u)) and Zg,g+1 =
exp(−ρXg,g+1) for g ≥ s+ 1.
Proposition 1:
a) The total random discounted reward is
(2.8) RD(s;u) = αVs +
K∑
g=s
[
Wg,g+1
g∏
m=s
Zm,m+1
]
,
where VK+1 = 0.
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Figure 2.2: Renal Disease Model Structure
b) If the sojourn times are independent (as in the case of an SMP), the total expected
discounted reward is
(2.9) E[RD(s;u)] = αVs +
K∑
g=s
[
Wg,g+1
g∏
m=s
Lm,m+1(γ)
]
,
where Ls,s+1(γ) = E(exp(−γXs,s+1(u)), the Laplace transform of Xs,s+1(u) and
Lm,m+1(γ) is the Laplace transform of Xm,m+1 for m > s. Further, γ = − log(θ)
in the discrete case and γ = ρ in the continuous case.
Part (a) of Proposition 1 is derived in Appendix 2.9.1. Part (b) follows from the
definition and independence of the Zm,m+1’s.
Remark : There are explicit expressions for the Laplace transform of many common
distributions. For example, the Laplace transform L(t) for Gamma(κ, η) is (1+ηt)−κ.
The exponential case corresponds to κ = 1.
2.3.3 Illustrative Application
Computation of CEA Metrics
We consider the renal-disease component of the model from the application in
Rosen et al. (2005) which involves assessing the benefits of angiotensin-converting en-
zyme (ACE) inhibitors, and construct an illustrative example using the same health
states, but different sojourn times and probabilities. ACE-inhibitors are commonly
available drugs that are used to treat a variety of health problems, including cardio-
vascular disease, renal disease, diabetes, high blood pressure, and migraines. They
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prevent the production of angiotensin II from angiotensin I. Angiotensin II is a sub-
stance in the tissues and blood that narrows blood vessels, resulting in increased
blood pressure and stress upon the heart. Generic ACE-inhibitors are widely avail-
able, resulting in relatively affordable pricing. The ACE-inhibitor ramipril was shown
to be effective in reducing MI, cardiovascular death, other cardiovascular events, and
nephropathy (renal disease) in the population aged 55 and older with diabetes (Ger-
stein et al., 2000). ACE-inhibitors are also an attractive treatment option because
they have relatively few side-effects. In this illustrative application, we consider the
effects of ACE-inhibitors on renal disease; in later examples, we also consider their
effect on cardiovascular disease.
Figure (2.2) shows the one-step progressive model with four states ordered from
healthiest to sickest: Normoalbuminuria, Microalbuminuria, Macoalbuminuria, and
End Stage Renal Disease (ESRD). The policy decisions being compared are: ‘1’: use
of ACE inhibitors (adherence), and ‘0’: no use of ACE-inhibitors (non-adherence).
The particular policy decision being considered is full coverage (no co-pay) of the
cost of ACE-inhibitors under Medicare for elderly diabetics, and we are specifically
interested in the effect on those who change from adherence to non-adherence due to
full coverage. In this case, it is assumed that all subjects receiving full reimbursement
for ACE-inhibitors will take them (adherence), and all subjects not receiving full
reimbursement for ACE-inhibitors will not take them (non-adherence).
We assume that all subjects have diabetes and start in the Normoalbuminuria
state. Table 2.1 provides the inputs needed to compute cost and QALYs. All patients
incur an annual cost of $3, 500 for routine medical treatment. The annual cost of
ACE-inhibitors (noted as the cost of treatment adherence) is $300 per subject. As is
usual in the literature, we take the discount rate for costs and QALYs, denoted by
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Table 2.1: Model Inputs: Disease Utilities, Costs, and Discount Rate
QALYs
Diabetes (Baseline Health) 0.88
ESRD 0.61
Annual costs $
Ongoing cost of care 3,500
Diabetes, Normoalbuminuria 1,000
Diabetes with Microalbuminuria 2,000
Diabetes with Macroalbuminuria 4,000
ESRD 80,000
Treatment Adherence 300
Table 2.2: Model Inputs: Disease Prevalence and Progression, Renal Disease Model
Parameter Name Non-Adherent Adherent
Sojourn Distribution Parameters, Gamma Distribution
Shape Parameters, κ
Normoalbuminuria to Microalbuminuria (κ1,2) 2 6
Microalbuminuria to Macoalbuminuria (κ2,3) 1 4
Microalbuminuria to ESRD (κ3,4) 1 2
ESRD to Dead (κ4,5) 0.1 0.1
Scale Parameter, η, (all transitions) 3 3
r, to be 3%(Gold et al., 1996).
The ACE inhibitors affect the sojourn-time distributions in the states, slowing
renal disease progression. We illustrate the computations with gamma sojourn time
distributions. The model parameters are given in Table 2.2. As an example of the
calculations, consider the evaluation of E(C0). We have
E(C0) = αV1 +W1,2L1,2 +W2,3L1,2L2,3 +W3,4L1,2L2,3L3,4 +W4,5L1,2L2,3L3,4L4,5,
since all the Ui,j’s are zero. We can compute each of the above elements: V1 = 4500
(the sum of ongoing cost of care and having diabetes with Normoalbuminuria), V2 =
5500, V3 = 7500, V4 = 80000, and V5 = 0. We take ρ = 0.03, so α = 1/.03. Further,
Lm,m+1 = (1+ηρ)
κm,m+1 , and as an example, L1,2 = (1+3×0.03)2 for the non-adherent
case. Form all this, we get E(C0) = $68, 639. Similar calculations show: E(C1) =
$123, 763, E(E0) = 8.7, and E(E1) = 19.0, resulting in µICER = 5, 352$/QALY.
The usual comparison value is λ = $50, 000, so ACE-inhibitors will be considered
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cost-effective. Alternatively, µNMB with λ = $50, 000 is $426, 326; since this is much
larger than the reference value of 0, there is a substantial benefit from using the
new treatment. We also computed the reward expected values for the case with
Weibull sojourn distributions with matching the first two moments matching those
of the gamma distributions used here, and the conclusions were similar, suggesting
that the results were robust to distributional assumptions in this case. The use of
analytical expressions facilitates such comparisons easily.
Parameter Uncertainty and Sensitivity Analysis
The reward estimates are only as reliable as the parameters used to calculate
them. We now illustrate how the uncertainty due to parameter estimation can be
easily quantified using the analytical expressions in this paper. Specifically, we want
to assess how much the conclusions of the CEA analysis depend on the uncertainty
in the estimated values of the unknown parameters.
Consider first a sensitivity analysis – how sensitive cost, QALYs, ICER, and NMB
are to small perturbations of the estimates of each individual parameter. One way
to do this is to compute the derivative of the output as a function of that input
parameter. The expression for the expected discounted reward is
(2.10)
E(RD(1; 0)) = αV1 +W1,2L1,2 +W2,3L1,2L2,3 +W3,4L1,2L2,3L3,4 +L4,5L1,2L2,3L3,4L4,5.
If we are interested in assessing the sensitivity to changes in the parameters κ1,2 and
κ2,3, we can compute the partial derivatives of E(RD(1; 0)) with respect to these
parameters and evaluate them at the estimated parameter values. This deriva-
tive shows the change in reward due to a one-unit change in the parameter at
the estimated values. Doing the calculations, ∂E(C0,D(1, 0))/∂κ2,3 = $9, 429, and
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∂E(C1,D(1, 0))/∂κ2,3 = $4, 836. The corresponding values for QALYs are:
∂E(E0,D(1, 0))/∂κ2,3 = 1.8, and ∂E(E1,D(1, 0))/∂κ2,3 = 0.9. Thus, the mean values
for non-adherent rewards are more sensitive to changes in parameter values. The
sensitivity values for all the parameters are given in Table 2.3.
We now discuss computation of the overall standard error by using Taylor series
approximation. Let Ê(R(1; 0)) = F (βˆ1, ..., βˆL) where the βˆj’s represent the esti-
mated parameters (transition probabilities, parameters of the state-occupancy dis-
tributions, etc.). Then, the Taylor series approximation for the variance of Ê(R(1; 0))
is Var[Ê(R(1; 0))] ≈ fTΣ f where f is the vector of partial derivative of F evaluated
at the estimated values and Σ is the variance-covariance matrix of the βˆj’s.
Suppose we have field data from n = 100 patients on the sojourn times in different
states. Usually, the field data will be subject to various forms of censoring (right,
left, interval, etc.), but for simplicity we assume here there is no censoring. Further,
suppose the values in Table 2.2 are the MLEs of the parameters when the data were
fitted to gamma distributions. We can use arguments from likelihood theory to get
the estimated information matrix and invert it to get the variance-covariance matrix
of the parameters. The details are available in standard textbooks and are omitted
here (see, for example, Bickel and Doksum (2001)).
The estimated variances and standard errors for costs and effectiveness are also
given in Table 2.3. As with the sensitivity analysis on individual parameters, the
standard errors for non-adherent rewards are larger than those for adherent rewards.
In practice, one is not likely to get maximum likelihood of the parameter estimates
under some parametric model. Rather, the summary data will consist of statistics
such as the mean and variance of the distributions and possibly their standard errors.
One would then have to estimate the underlying parameters of a parametric model
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Table 2.3: Partial Derivatives of Reward Functions
Variable C0 C1 E0 E1
κ1,2 7,012 3,123 1.8 0.9
κ2,3 9,429 4,836 1.8 0.9
κ3,4 13,866 7,262 1.8 0.9
κ4,5 161,404 81,307 1.2 0.6
η 17,073 19397 2.3 3.4
σˆ2 1.81562× 107 3.76968× 106 0.23 0.09
σˆ 4, 261 1, 942 0.48 0.30
for the sojourn distribution by matching the moments. For a gamma distribution,
since the mean is κη and the variance is κη2, we get ηˆ = (sample variance)/(sample
mean) and κˆ = (sample mean)2/(sample variance). We can then use Taylor series
approximation to get the standard errors of the estimated parameters.
Similar methods can be used to compute the standard errors of CEA metrics such
as ICER and NMB. See, for, example, O’Brien et al. (1994). In this example, the
estimated standard error for µICER is 245 and that for µNMB is 28,589. Recall that
the estimates for µICER and µNMB at λ = 50, 000 were 5, 352$/QALY and $426, 326
respectively. So, the standard errors due to parameter uncertainty are small in
comparison, so the conclusion of cost-effectiveness still holds.
If the computations of the derivatives is difficult, one can use a simple Monte
Carlo approach to simulate from the distributions of the input variables (Kennedy
and Gentle, 1980; Givens and Hoeting, 2005). These methods are all well known in
the statistical literature. They are not necessary in this single-step case, but we will
demonstrate their application in the more complicated multi-step case in the next
section.
2.4 Multi-Step Progressive: Stationary Case
As before, the results for the multi-step case are developed first for a single subject
who is in state s (with s ≤ K) at the start of the study and has spent a period time
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u in that state.
2.4.1 Life Time Distributions
We can see from Figure (2.1) that the subject can reach the absorbing state
through many possible paths. Suppose the subject moves through the sequence of
states {s = J1 < J2 < ... < Jk < Jk+1 = K + 1} where Ji’s denote the random
indices of the visited states and k is the random number of states visited before
failure. Then,
(2.11) T (s;u) = Is,J2 × IJ2,J3 · · · × IJL,K+1 (Xs,J2(u) +XJ2,J3 + · · ·+XJL,K+1) .
A discrete-event simulation approach might proceed by mimicking the above process
– select J2 randomly according to the set of transition probabilities, simulateXs,J2(u),
select J3 randomly according to the transition probabilities, simulate XJ2,J3 , and so
on.
In the stationary case, the transition probabilities (and hence the indicator func-
tions in equation (2.11) are independent of time. Thus, we can first condition on the
indicator function (the path), compute the sum of the sojourn times for the path,
and then sum over all possible paths. This leads to a representation of the total
(residual) lifetime as
(2.12) T (s;u) =
∑
j
I
(j)
s,i2,...,ikj ,K+1
(
X
(j)
s,i2
(u) +X
(j)
i2,i3
+ · · ·+X(j)ikj ,K+1
)
,
where the sum j is over all possible paths {s < i2 < ... < ikj < K+1} from the initial
state s to the absorbing state K + 1. Here I
(j)
s,i2,...,ikj ,K+1
= Is,i2 × Ii2,i3 × · · · Iikj ,K+1.
Note that there are J = 2K−s possible such paths. Further, kj, the number of states
visited before absorption, depends on the path j. For simplicity, we suppress the
superscript notation j in the rest of the paper. Again, the special case where the
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subject just starts in state 1 at the beginning of the study is obtained by taking
s = 1 and u = 0 in the above expression.
As an example, consider the case with 4 states and s = 1. There are four possible
paths: 1→ 2→ 3→ 4, 1→ 2→ 4, 1→ 3→ 4, and 1→ 4, so
T (1, u) = I{1,2,3,4}(X1,2(u) +X2,3 +X3,4) + I{1,2,4}(X1,2(u) +X2,4)(2.13)
+ I{1,3,4}(X1,3(u) +X3,4) + I{1,4}X1,4(u).
The random variables X1,2(u) in the first and second components of the sum in
equation (2.13) are independent realizations of the same random variable. The reason
for independence is that a given subject can take only one of the 4 possible paths,
and different subjects are independent of each other. A similar comment applies to
other cases.
The lifetime distribution is a finite mixture with J elements. Its density can be
expressed as
(2.14) fT (t|s;u) =
∑
j
ps,i2,...,ikj ,K+1
(
fs,i2(t;u) ∗ fi2,i3(t) ∗ ... ∗ fikj ,K+1(t)
)
,
where, as before, the sum j is over all possible paths. Here, ps,i2,...,ikj ,K+1 = E(Is,i2,...,ikj ,K+1) =
ps,i2 × pi2,i3 × · · · × pikj ,K+1, fij ,ik(t) is the density of Xij ,ik , fs,ik(t;u) is the density
of Xs,i2(u) and ∗ denotes convolution.
From standard properties of mixture distributions (McLachlan and Peel, 2000),
one can express the mean of the life-time distribution as
(2.15) E(T (s;u)) =
∑
j
ps,i2,...,ikj ,K+1
(
µs,i2(u) + µi2,i3 + ...+ µikj ,K+1
)
,
where µi,j is the mean of Xi,j and µs,i1(u) is the mean of Xs,i1(u). The variance
expressions are discussed in Appendix 2.9.3.
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Example: Consider the four-state model in equation (2.13). Suppose s = 1, u = 0,
i.e., the subject starts in state 1 and has not yet spent any time in that state. Further
suppose the distributions ofXi,j are Gamma(κi,j, η) and they are independent. Recall
that the sums of independent gamma distributions with the same scale parameter η
are also gamma. So,
fT (t|1; 0) = p1,2,3,4 Gamma(κ1,2 + κ2,3 + κ3,4, η)
+ p1,2,4 Gamma(κ1,2 + κ2,4, η)
+ p1,3,4 Gamma(κ1,3 + κ3,4η)
+ p1,4 Gamma(κ1,4, η),
a mixture of gamma distributions. The mean of a Gamma(κ, η) distribution is κη.
This can be used to calculate the mean of the lifetime as
(2.16)
E(T (1; 0)) = η (p1,2,3,4(κ1,2 + κ2,3 + κ3,4) + p1,2,4(κ1,2 + κ2,4) + p1,3,4(κ1,3 + κ3,4) + p1,4κ1,4) .
2.4.2 Reward Random Variables and Expected Rewards
No Discounting
Again, consider first the case where there is no discounting of rewards over time.
The total random cost for an individual subject is
R(s;u) =
∑
Is,i2,...,ikj ,K+1
(
Vs,i2X
j
s,i2
(u) + Us,i2+ Vi2,i3X
j
i2,i3
+ Ui2,i3
+ · · ·+ Vikj ,K+1X
j
ikj ,K+1
+ Uikj ,K+1
)
,
(2.17)
which can be written in a compact form as
R(s;u) =
∑
j
Is,i2,...,ikj ,K+1
 kj∑
g=1
Uig ,ig+1 + Vi1X
j
i1,i2
(u) +
k∑
g=2
VigX
j
ig ,ig+1
 ,(2.18)
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where i1 = s and ikj + 1 = K + 1. The expected reward can be calculated from this
as
E(R(s;u)) =
∑
j
ps,i2,...,ikj ,K+1
 kj∑
g=1
Uig ,ig+1 + Vi1µi1,i2(u) +
k∑
g=2
Vigµig ,ig+1
 ,(2.19)
where, as before, µi,j is the mean of Xi,j and µi,j(u) is the mean of Xi,j(u). The
variance of the expression is a straightforward extension of the single-step case.
Discounting
The case with discounting is of more interest. The results for the multi-step case
can be obtained by combining the results for all possible paths. The derivations are
given in Appendix 2.9.2. We just provide the main result here.
Recall that in the case with discrete time, the rewards are discounted by a factor
r per unit time. Let θ = 1
(1+r)
. For continuous time, the discount rate is ρ, so the
discount for a time of length x is exp(−ρx). Let
(2.20) Wig ,ig+1 = Uig ,ig+1 + α(Vig+1 − Vig),
for VK+1 = 0 where α =
θ
(1−θ) for discrete time and α = 1/ρ for continuous time.
Proposition 2:
a) The total random discounted reward is
(2.21) RD(s;u) =
∑
j
Is,i2,··· ,ikj ,K+1
αVs + kj∑
g=1
[
Wig ,ig+1
g∏
m=1
Zim,im+1
] ,
where i1 = s and ikj + 1 = K + 1.
b) If the sojourn times are independent (as in the case of an SMP), the total expected
discounted reward is
(2.22) E(RD(s;u)) =
∑
j
ps,i2,··· ,ikj ,K+1
αVs + kj∑
g=1
[
Wig ,ig+1
g∏
m=1
Lim,im+1(γ)
] ,
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where Lim,im+1(γ) is the Laplace transform of Xim,im+1 for m ≥ 2 and of Xs,i2(u) for
m = 1, and γ = − log(θ) in the discrete case and γ = ρ in the continuous case.
Example: Consider again the 4-state model in equation (2.13). Taking u = 0 and
s = 1,
R(1; 0) = I1,2,3,4(αV1 +W1,2Z1,2 +W2,3Z1,2Z2,3 +W3,4Z1,2Z2,3Z3,4)
+ I1,2,4(αV1 +W1,2Z1,2 +W2,4Z1,2Z2,4)
+ I1,3,4(αV1 +W1,2Z1,3 +W3,4Z1,2Z2,4)
+ I1,4(αV1 +W1,4Z1,4).
If it is a semi-Markov model, the expected reward is obtained by replacing Zi,j in
the above expression with its Laplace transform. Suppose the state-occupancy times
are gamma; i.e., Fi,j =Gamma(κ, η). Its Laplace transform is (1 + tη)
−κ. So, the
expected reward for a gamma semi-Markov process can be written as
E(R(1; 0)) = p1,2p2,3p3,4(αV1 +W1,2(1 + tη)−κ1,2 +W2,3(1 + tη)−κ1,2(1 + tη)−κ2,3
+W3,4(1 + tη)
−κ1,2(1 + tη)−κ2,3(1 + tη)−κ3,4)
+ p1,2p2,4(αV1 +W1,2(1 + tη)
−κ1,2 +W2,4(1 + tη)−κ1,2(1 + tη)−κ2,4)
+ p1,3p3,4(αV1 +W1,3(1 + tη)
−κ1,3 +W3,4(1 + tη)−κ1,3(1 + tη)−κ3,4)
+ p1,4(αV1 +W1,4(1 + tη)
−κ1,4).
The exponential distribution is a special case with κi,j = 1.
2.4.3 Illustrative Application
We now consider the cardiovascular disease (CVD) component of the application
in Rosen et al. (2005). The structure, shown in Figure (2.3), is a multi-step process
with four states: healthy (no history of MI), a history of one MI (which was survived),
a history of two MIs (both of which were survived), and death due to MI. We make
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Figure 2.3: Cardiovascular Disease Model Structure
Table 2.4: Model Inputs: Disease Utilities, Costs, and Discount Rate
QALYs
Diabetes (Baseline Health) 0.88
MI 0.88
Annual costs $
Ongoing cost of care 3,500
History of MI 2,500
Acute MI (impulse cost) 35,000
Treatment Adherence 300
a simplifying assumption that a third MI would automatically be fatal. In addition,
we restrict attention to deaths due to MI only. We assume that the subject starts
with no history of MI. Again, the intervention in question is full cost-coverage of
ACE inhibitors in diabetics.
The sojourn and impulse costs and QALYs are in Table 2.4. The transition proba-
bilities and sojourn time distributions are in Table 2.5. Note that the state-transition
probabilities do not vary with treatment, but the sojourn time distributions do.
The possible paths through this MI disease process are:
1. Healthy → 1 MI → 2 MI → Dead
2. Healthy → 1 MI → Dead
3. Healthy → Dead
For notational simplicity, we will refer to the healthy state as state 1, survival of a
single MI as state 2, survival of 2 MI as state 3, and death as state 4.
This application differs from the earlier on renal disease in two ways. First, there
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Table 2.5: Model Inputs: Disease Prevalence and Progression, MI Model
Parameter Name Non-Adherent Adherent
Transition Probability
Healthy to MI (p1,2) 0.7 0.7
Single MI to second MI (p2,3) 0.7 0.7
Healthy to Dead (p1,4) 0.3 0.3
Single MI to Dead (p2,4) 0.3 0.3
Second MI to Dead (p3,4) 1 1
Sojourn Distribution Parameters, Gamma Distribution
Shape Parameter, κ
Healthy to MI (κ1,2) 3 4
Single MI to second MI (κ2,3) 1 2
Healthy to Dead (κ1,4) 8 10
Single MI to Dead (κ2,4) 3 4
Second MI to Dead (κ3,4) 1 1
Scale Parameter, η, (all transitions) 3 3
are multiple paths for which probabilities are needed. We can calculate the proba-
bility of each path using the parameters in Table 2.5. For instance, the probability
of path 1 → 2 → 3 → is p1,2p2,3p3,4 = 0.7 × 0.7 × 1 = 0.49. Second, an MI has
an impulse cost, whereas the renal disease model had only sojourn rewards. So, for
example, the non-adherent cost W1,2 is calculated per Equation (2.20) as
WC01,2 = 35000 +
1
.03
((3500 + 1000 + 2500)− (1000 + 3500)) = 118, 333.3.
The expected rewards can be calculated using the transition probabilities and
gamma sojourn distribution parameters in Table 2.5 and Equation (2.22). They are:
E(E0) = 11.6, E(E1) = 14.2, E(C0) = $117, 829, E(C1) = $133, 766. So we have
µICER = 5, 595$/QALY, or equivalently with λ = 50, 000, an µNMB = $118, 540.
As in the renal case, the treatment will be considered cost-effective. We also did
the analysis with Weibull distributions with the first two moments matched to the
gamma sojourn distributions, and the results were very similar.
We now turn to an examination of parameter uncertainty and demonstrate the
use of Monte Carlo simulation. Specifically, we simulate the distribution of mean
rewards as the parameter values in the models change. Since the parameter values
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for the gamma distributions have to be positive, we assumed they were distributed
according to a lognormal distribution. The transition probabilities were simulated
according to a beta distribution. The parameters of these distributions were chosen
to reflect the values in Table 2.5.
We simulated 10, 000 patients per path. The densities of E(E1)−E(E0), E(C1)−
E(C0), µICER, and µNMB (calculated at λ = 50, 000) are shown in Figure (2.4). These
distributions capture the uncertainty due to parameter estimation. We see that the
estimated densities for the differences in mean costs and effectiveness do not contain
0, providing unambiguous evidence for the presence of a treatment effect for all the
reward measures. Also, the support of the density of µNMB is above 0 and the support
of the density of µNMB is below the willingness-to-pay of $50, 000/QALY.
2.5 Combining Subject-Level Results to Population Level
The reward expressions and computations presented so far are for a single subject
who starts in a given state and has already spent a certain amount of time there. To
obtain population-level results, suppose there are N subjects in the population, and
Ns subjects are in state s at the start of the study, s = 1, 2, ..., K. Further, suppose
the Ns subjects have spent us,1, us,2, ..., us,Ns units of time in state s, for s = 1, ..., K.
Then, the total (random) reward for the population is just
TRP =
K∑
s=1
Ns∑
n=1
RD(s;us,n),
where RD(s;us,n) is the discounted reward for an individual subject. The average
random reward per subject is
E(TRP ) =
K∑
s=1
Ns∑
n=1
WsRD(s;us,n),
where Ws = Ns/N , the proportion of subjects who are in state s.
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Figure 2.4: Densities of Mean Estimates. Figure A: E(E1) − E(E0) = µ1(E) − µ0(E). Figure B:
E(C1)− E(C0) = µ1(C)− µ0(C). Figure C: µICER. Figure D: µNMB.
In DES, the population of interest in a conceptual one, so one has to select the
values for Ns and us,n. The values of Ns are typically selected to represent the profiles
of the actual population of interest. The values of us,n can be simulated using the
information about state-occupancy distributions Xs,g; g > s.
The expected reward expressions can be used to compute average costs and
QALYs for the various policy decisions and compute the CEA metrics such as ICER
and NMB. As discussed, the unknown parameters for the transition probabilities and
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Figure 2.5: Four-state Model with Multiple Causes of Death. Left panel: Original 4-state model.
Right panel: Model with separate causes of death.
expected values of the sojourn times have to be estimated, typically from historical
data.
2.6 Extensions
Thus far, we have focused on stationary semi-Markov models. The results extend
easily to the case with static covariates (covariates that do not change with time
such as gender). Other covariates such as age, weight, and body mass index will
vary with time. Including them in the analysis will introduce non-stationarity which
is more difficult to handle. We discuss the nonstationary case in this section, along
with an extension to competing causes of death.
2.6.1 Multiple Causes of Death: Competing Risks
One is generally interested in analyzing policy decisions in the presence of multiple
causes of death. If the costs and QALYs associated with all the causes of death are
the same, we can collapse them into one state and use the analysis discussed thus
far. In practice, however, this will not be the case, and we have to treat them
separately. In fact, there may be other reasons for analyzing the different types of
death separately, such as preserving information about failure modes for analysis.
Analysis of multiple causes of death does not pose serious complications for the
analysis. The additional causes of death have to added as new states. Then, one has
to enumerate the different paths to absorption and use the results in the same way as
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before. Some simplifications can be obtained in special cases, such as the single-step
case in the right panel of Figure (2.5). Then, only the last component of the lifetime
and reward expressions change. Suppose there is one additional cause of death.
Then, for the example in Figure (2.5), the life-time expression in Equation (2.3)
changes to
(2.23) T (s;u) =
K−1∑
g=s
(Xg,g+1) +
2∑
d=1
(IK,K+dXK,K+d) ,
and the total discounted random reward from equation (2.8) to
(2.24)
RD(s; j) = αVs+
K−1∑
g=s
[
Wg,g+1
g∏
m=s
Zm,m+1
]
+
2∑
d=1
IK,K+d
[
WK,K+dZK,K+d
K−1∏
m=s
Zm,m+1
]
.
2.6.2 Non-stationary cases
The analysis discussed thus far has been restricted to stationary cases. Non-
stationarity can arise from several sources: non-stationary transition probabilities,
sojourn distributions, time-varying covariates, or a combination. For example, the
sojourn time distributions and the transition probabilities can depend on (calendar)
time or ‘age’ of the patient.
The formulation of semi-Markov processes are general enough to handle these.
Recall the general definition of the semi-Markov kernel in Section 2 with Qi,j(t1, t2) =
Fi,j(t1, t2)pi,j(t1) as the semi-Markov kernel. Here t1 denotes the time at which the
subject transitioned from state i to state j. However, it is not possible to obtain
analytical expressions for non-stationary cases in general. We discuss alternatives in
this section.
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Non-stationary sojourn distributions with stationary transition probabilities
Semi-Markov models with non-stationary sojourn distributions but stationary
transition probabilities have been referred to as additive semi-Markov processes
(Janssen and Manca, 2006, 2007). When the transition probabilities are station-
ary, the general expressions in Section 2.4 still hold. In particular, the (residual)
time-to-failure can continue to be expressed as
(2.25) T (s;u) =
∑
j
Is,i2,...,ikj ,K+1
(
Xs,i2(u) +Xi2,i3 + · · ·+Xikj ,K+1
)
,
and the expressions for the random rewards are also the same. However, the ran-
dom variables Xig ,ig+1 ’s are no longer independent; in particular, their distributions
depend on the times at which the subject transitioned from state ig to ig+1. To be
specific, consider a path {s < i2 < ... < ikj < K + 1}, and let
(2.26) Sim(u) = Xs,i2(u) + · · ·+Xim−1,im
be the time at which the subject transitioned into state im. Then, the distribution
of Xim,im+1 depends on Sim(u). For example, the distributions could be exponential
with mean exp(βim,im+1Sim).
Because of the dependence structure, the expectations of the lifetime and rewards
cannot be derived in analytical form in general. But it is easy to get these values
through direct Monte Carlo simulation. For each possible path, one first simulates
Xs,i2(u), then the conditional random variables [Xi2,i3|Xs,i2(u)], [Xi3,i4|Xs,i2(u), Xi2,i3 ]
etc. This process is repeated N times to get a Monte Carlo average, repeated for
all possible paths and weighted using the transition probabilities to get the overall
expected rewards. This is still much easier than setting up a discrete-event simula-
tion framework. It also has the advantage that all possible paths are sampled and
weighted appropriately in the computation of the CEA metrics.
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General non-homogeneous case
We turn now to the more general situation where both the transition probabilities
and the sojourn time distributions are non-stationary. Situations with time-varying
covariates (such as health status, age, etc.) also fall into this category.
We can write the time-to-failure as in Section 2.4,
(2.27) T (s;u) = Is,J2 × IJ2,J3 · · · × IJL,K+1 (Xs,J2(u) +XJ2,J3 + · · ·+XJL,K+1) ,
but now both the indicator functions for the transitions and the sojourn times depend
on the Sim(u)’s in equation (2.26). We can take the expectation of T (s, u) by first
conditioning on the sojourn times and then taking the expectation with respect to the
distributions of the sojourn times. Doing this allows us to represent the expectation
as
E[T (s;u)|sojourn times] =
∑
j
ps,i2(Ss(u))p(i2, i3)(Si2(u))× · · · × pikj ,K+1(Sikj)
×
(
Xs,i2(u) +Xi2,i3 + · · ·+Xikj ,K+1
)
,
(2.28)
where p(i2, i3)(Si2(u)) = E[Ii2,i3(Si2(u))|sojourn times]. A corresponding expression
will hold for the random rewards. Note that the sum is still over all possible paths.
These conditional transition probabilities have explicit forms as they are given by the
multi-state model. For example, one possible form is p(i2, i3)(t) = 1 − exp(t/ηi1,i2),
indicating that the probability of transition increases with time.
Again, it is not possible to obtain analytical expressions for the expected lifetime
and rewards in general. But the direct Monte Carlo method outlined in the last
subsection extends readily to this situation also.
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Comparison with Discrete-Event Simulation
The advantages of the approaches developed in the paper are clear when there are
analytical expressions for the expected rewards. There is no need to set up a discrete
event simulation framework and simulate sample paths through the multi-state. The
advantages are less evident when analytical expressions are not available and one
still has to use Monte Carlo methods to compute the expectations. Nevertheless, the
direct approaches discussed for the non-stationary cases are easier to work with and
implement than simulating a large-scale multi-state model. The only computational
challenge is in enumerating all the possible paths through the system. This is not a
difficult problem.
A more important advantage is that the approaches outlined here evaluate the
random variables for each possible path, weight them according to the probability
of using that path and obtain an overall average. In DES, on the other hand, not
all possible paths will be used; rather the paths are sampled in each simulation
replication according to their likelihood, so paths with very small probabilities have
a low probability of being sampled. This may be fine for the purposes of getting
expected lifetimes but not for computing rewards. Small probability paths may have
high costs.
Also, the approaches described here examine each of these paths, giving us direct
information about all possible elements that go into the average calculations. The
comparison between DES and the approaches here are similar to the comparison
between simple random and stratified sampling. The latter sample from each stratum
(mixture component or path in our set up) and hence provide detailed information
about the population of interest as well as global information about the average.
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2.7 Application
This section combines the renal disease model and the CVD model previously
discussed so that we can illustrate the results on a more complex application. This
example is very similar to the application in Rosen et al. (2005), but it has been
modified to be progressive, stationary, and with sojourn times that are distributed
according to the gamma distribution. Further, only deaths due to renal disease or
MI are considered; competing risk deaths, which vary with time, are not included.
Figure (2.6) shows part of the multi-step process. The mode of patient death
determines the cost of the death event; in particular, there is an impulse cost associ-
ated with dying of MI, as reflected in Table 2.7. As a result, the two modes of death
are represented as separate health states, as shown in Figure (2.6), and we use the
competing risk extension discussed in Section 2.6. All patients enter the process in
the Normoalbuminuria (healthy) state. To simplify the figure, we have not shown
included additional paths from the relatively healthy states to death caused by MI;
but any patient may die due to MI from any health state. Not all transitions between
states in the model are possible; for instance, a patient cannot progress directly from
Normoalbuminuria to ESRD. Thus, while in theory there are 214−2 = 4096 patient
paths, there are only 49 paths with positive probability. Even 4096 can be handled
with relative ease if we have analytical solutions. The full set of probabilities and the
shape parameters for the gamma sojourn-time distributions, κi,j, for all transitions
in the full model with positive probability are given in Table 2.6. All transitions
are assumed to have scale parameter η = 3, and all patients are assumed to start
with Normoalbuminuria and no history of MI. In the table, we abbreviate the Nor-
moalbuminuria state as Normo, Microalbuminuria as Micro, and Macroalbuminuria
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Figure 2.6: Application Structure.
as Macro. Additionally, MI1 and MI2 denote surviving 1 and 2 MIs, respectively.
Finally, DMI denotes death due to MI, and DESRD denotes death due to ESRD.
The probabilities and sojourn time distribution parameters are more involved
in this bigger model. One reason is that the progression of renal disease affects the
progression of cardiovascular disease; notably, those with Macroalbuminuria progress
more quickly to an MI. Additionally, in the earlier cases with just renal disease or
CVD, medication adherence affected only the sojourn time distribution and not the
transition probabilities; in this combined model, transition probabilities also change
as a result of medication adherence. In general, adherence to medication increases
the time to any event, and decreases the probability of fatal cardiovascular disease
events. Adherence also increases the probability that the next state transition will
be into the next renal disease state, rather than into the next cardiovascular disease
state.
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Table 2.6: Model Inputs: Disease Prevalence and Transition Probabilities, Full Model
Transition Probability Scale Parameter, κ
Parameter Name Non-Adherent Adherent Non-Adherent Adherent
Normo, MI1 0.32 0.4 3 4
Normo to DMI 0.14 0.20 8 10
Normo to Micro 0.55 0.34 2 6
Normo, MI1 to Normo, MI1 0.48 0.59 1 2
Normo, MI1 to DMI 0.20 0.25 3 4
Normo, MI1 to Micro, MI1 0.32 0.17 2 6
Normo, MI2 to DMI 0.68 0.83 1 1
Normo, MI2 to Micro, MI2 0.32 0.17 2 6
Micro to Micro, MI1 0.19 0.37 3 4
Micro to DMI 0.08 0.16 8 10
Micro to Macro 0.73 0.47 1 4
Micro, MI1 to Micro, MI2 0.34 0.52 1 2
Micro, MI1 to DMI 0.15 0.22 3 4
Micro, MI1 to Macro, MI1 0.52 0.52 1 4
Micro, MI2 to DMI 0.49 0.74 1 1
Micro, MI2 to Macro, MI2 0.52 0.26 1 4
Macro to Macro, MI1 0.41 0.44 1 2
Macro to DMI 0.17 0.19 3 4
Macro to ESRD 0.42 0.37 1 2
Macro, MI1 to Macro, MI2 0.54 0.57 1 1
Macro, MI1 to DMI 0.23 0.24 1 1
Macro, MI1 to ESRD, MI1 0.23 0.19 1 2
Macro, MI2to DMI 0.77 0.85 0.3 1
Macro, MI2 to ESRD, MI2 0.23 0.15 1 2
ESRD to ESRD, MI1 0.17 0.13 1 2
ESRD to DMI 0.07 0.06 3 4
ESRD to DESRD 0.76 0.81 0.3 0.3
ESRD, MI1 to ESRD, MI2 0.31 0.25 1 1
ESRD, MI1 to DMI 0.13 0.14 1 1
ESRD, MI1 to DESRD 0.56 0.60 0.3 0.3
ESRD, MI2 to DMI 0.44 0.56 0.3 1
ESRD, MI2 to DESRD 0.38 0.62 0.3 0.3
The reward structure is shown in Table 2.7. There is one complication in the
reward structure for the combined model because a patient’s health state is defined
by a combination of the renal disease state and the CVD state. As a result, both
costs and QALYs are dependent upon the rewards for each disease. QALYs are
multiplicative across the two disease (so an individual with Normoalbuminuria and
a history MI would have an overall utility of 0.88× 0.88), and costs are additive, so
the same individual would have a sojourn cost per unit time of 1000 + 3500 + 2500.
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Table 2.7: Model Inputs: Disease Utilities, Costs, and Discount Rate
QALYs
Diabetes (Baseline Health) 0.88
ESRD 0.61
MI 0.88
Annual costs $
Treatment Adherence 300
Ongoing cost of care 3500
Diabetes, Normoalbuminuria 1000
Diabetes with Microalbuminuria 2000
Diabetes with Macroalbuminuria 4000
ESRD 80000
History of MI 2500
Acute MI (transition cost) 35000
Discount Rate, % 3
The expected reward and probability of each path can be calculated in a manner
similar to in the CVD case, but for the full set of 49 paths this time. The result
is E(E0) = 12.1, E(E1) = 17.1, E(C0) = $151, 307, E(C1) = $153, 180, so µICER =
375 $/QALY, and µNMB = $243, 868, resulting in the intervention being very cost-
effective even for the combined model.
We can use the Monte Carlo simulation of the Taylor Series method introduced in
the multi-step section to determine the uncertainty due to parameter estimation. The
set up is the same as in the CVD case. The densities of E(E1)−E(E0), E(C1)−E(C0),
µICER, and µNMB (calculated at λ = 50, 000) are shown in Figure (2.7). The density
for E(C1) − E(C0) contains 0, so the evidence on whether the intervention reduces
cost is a bit ambiguous. This is also reflected in the distribution for µICER. However,
the support of the density for µNMB is quite a bit to the right of 0, so based on
this metric, one would conclude that the treatment is effective even after taking into
account parameter uncertainty.
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Figure 2.7: Densities of Mean Estimates. Figure A: E(E1) − E(E0) = µ1(E) − µ0(E). Figure B:
E(C1)− E(C0) = µ1(C)− µ0(C). Figure C: µICER. Figure D: µNMB.
2.8 Conclusion
This paper has developed analytical methods for computing cost-effectiveness
metrics with stationary semi-Markov processes. For non-stationary cases, direct
Monte-Carlo simulation has been proposed as an alternative to discrete event sim-
ulation. These methods are considerably easier to implement and use with CEA.
Additional advantages have been noted in the paper. Common aspects of CEA,
including sensitivity analysis, are also easily performed within this framework, and
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were demonstrated in this paper. Some common extensions, to multiple causes of
death and to non-stationary models, were also demonstrated.
While the results in the paper have been restricted to progressive models, they can
be extended to non-progressive (recurrent) models. As a practical matter, however,
nearly all disease models can be built to be progressive through the addition of more
states. While analysts have previously been reluctant to expand the state-space
due to computational concerns in traditional DES, state-space expansion is less of a
concern with the methods in this paper.
2.9 Appendix
2.9.1 Proof of Proposition 1
Single-step Discrete case
We consider the discrete case first. Let fg,g+1(x), s < g ≤ K, be the prob-
ability mass function (pmf) of Xg,g+1 and fs,s+1(x;u) be the conditional pmf of
[Xs,s+1|Xs,s+1 ≥ u].
We compute the total rewards associated with the fixed components, Us,s+1 and
Ug,g+1, s < g ≤ K, that are incurred at the time of transition. The subject starts in
state s and spends an amount of time Xs,s+1(u) in state s before moving to state s+1,
at which time s/he incurs a reward of Us,s+1. So this amount has to be discounted
by θXs,s+1(u) (recall that θ = 1
1+r
). The subject then spends Xs+1,s+2 time units in
state s+ 1 before moving to state s+ 2. So the reward Us+1,s+2 has to be discounted
by θXs,s+1(u)+Xs+1,s+2 . Repeating this argument, we get the fixed reward (reward due
to transitions) over the remaining life of a subject as
FRD(s;u) = Us,s+1θ
Xs,s+1(u) + Us+1,s+2θ
(Xs,s+1(u)+Xs+1,s+2) + ...
+ UK,K+1θ
(Xs,s+1(u)+Xs+1,s+2+...+XK,K+1).
(2.29)
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Define Zs,s+1 = θ
Xs,s+1(u) and Zm,m+1 = θ
Xm,m+1 for m ≥ s + 1. Then, we can write
the discounted fixed reward FRD(s;u) in a compact form as
(2.30) FRD(s;u) =
K∑
g=s
(
Ug,g+1
g∏
m=s
Zm,m+1
)
.
Consider now the variable reward that depends on the amount of time spent in
the different states (sojourn time). Again, the subject starts in state s and spends
an additional Xs,s+1(u) time units in state s. So the total discounted reward for this
period is Vs(θ
1 + ...+θXs,s+1(u)), which can be expressed as Vsθ(1−θXs,s+1(u))/(1−θ).
The subject then moves to state s+ 1 and spends an additional Xs+1,s+2 time units.
So the total discounted reward for this period is Vs+1θ
Xs,s+1(u)(θ1 + · · ·+ θXs+1,s+2(u))
which can be represented as Vs+1θ
Xs,s+1(u)(1 − θXs+1,s+2(u))/(1 − θ). So the total
variable reward over the remaining life of the subject is
V RD(s;u) =
θ
(1− θ)
(
Vs(1− θXs,s+1(u)) + (Vs+1θXs,s+1(u))(1− θXs+1,s+2) + · · ·
+(VKθ
(Xs,s+1(u)+Xs+1,s+2+...+XK−1,K)(1− θXK,K+1)))
(2.31)
=
θ
(1− θ) (Vs + (Vs+1 − Vs)Zs,s+1 + (Vs+2 − Vs+1)Zs,s+1Zs+1,s+2 + · · ·
+(VK − VK−1)Zs,s+1...ZK−1,K − (VKZs,s+1...ZK,K+1))
(2.32)
=
θ
(1− θ)
(
Vs +
K∑
g=s
(Vg+1 − Vg)
g∏
m=s
Zm,m+1]
)
(2.33)
where VK+1 = 0.
The fixed and variable costs can be combined to get the total (random) reward
as follows. Let
Wg,g+1 = Ug,g+1 +
θ
(1− θ)(Vg+1 − Vg).
Then, the total discounted random reward RuD(s) can be written in a compact form
51
as
(2.34) RD(s;u) =
θ
(1− θ)Vs +
K∑
g=s
[Wg,g+1
g∏
m=s
Zm,m+1].
This proves part (a) of Proposition 1 for the discrete case.
From the independence of the Xm,m+1’s, we get the expected discounted reward
as
(2.35) E(RD(s;u)) =
θ
(1− θ)Vs +
K∑
g=s
[Wg,g+1
g∏
m=s
E(Zm,m+1)].
Let Lm,m+1(γ) be the Laplace transform of Xm,m+1 for m > s and of Xs,s+1(u)
for m = s. Then, E(Zi,j) = E(θXm,m+1) = Lm,m+1(− log(θ)). This proves part (b) of
Proposition 1 for the discrete case.
Single-step Continuous Case
The proofs for the continuous case are very similar to the discrete case. For
completeness, we give some of the details below. Let fg,g+1(x) be the probability
density function (pdf) of Xi,j, s < g ≤ K, and fs,s+1(u) be the conditional pdf
of [Xs,s+1|Xs,s+1 ≥ u]. The main difference between the discrete and continuous
cases is in the discounting of the rewards. The discounting factor in continuous
time is exp(−ρx), for a time of length x with continuous discount rate ρ. Again, let
the rewards associated with the fixed components be Ug,g+1 and Us,s+1, incurred at
transition. As before, the subject starts at state s and spends Xs,s+1(u) time units in
state s before moving to state s+1. Us,s+1 is discounted at the time of the transition,
to get Us,s+1 exp(−ρXs,s+1(u)). The subject then spends Xs+1,s+2 time units in state
s+ 1 before moving to state s+ 2, so the resulting total discounted reward from the
second transition is Us+1,s+2 exp(−ρ(Xs,s+1(u) +Xs+1,s+2)). We see that the form of
the discounting is the same as the discrete case except that θx is now replaced by
exp(−ρx).
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Define Zm,m+1 = exp(−ρXm,m+1) for m > s and Zs,s+1 = exp(−ρXs,s+1(u)).
Then, as in the discrete case, we can write the discounted fixed reward FRD(s;u)
compactly as
(2.36) FRD(s;u) =
K∑
g=s
(
Ug,g+1
g∏
m=s
Zm,m+1
)
.
Following the same arguments as in the discrete case, we can write total variable
reward over the remaining life of the subject compactly as
(2.37) V RD(s;u) =
1
ρ
(
Vs +
K∑
g=s
[(Vg+1 − Vg)
g∏
m=s
Zm,m+1]
)
where VK+1 = 0.
Let
Wg,g+1 = Ug,g+1 +
1
ρ
(Vg+1 − Vg).
The fixed and variable costs can be combined to get the total (random) reward
RD(s;u) as
(2.38) RD(s;u) =
1
ρ
Vs +
K∑
g=s
[Wg,g+1
g∏
m=s
Zm,m+1].
This proves part (a) of Proposition 1 for the continuous case.
From this, we see that expected total discounted reward in the continuous case
has the same form as the discrete case:
(2.39) E(RD(s;u)) =
1
ρ
Vs +
K∑
g=s
[Wg,g+1
g∏
m=s
E(Zm,m+1)].
Let Lm,m+1(γ) be the Laplace transform of Xm,m+1 for m > s and of Xm,m+1(u)
for m = s. Then, E(Zm,m+1) = E(exp(−ρXm,m+1)) = Lm,m+1(ρ). This proves part
(b) of Proposition 1 for the continuous case.
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2.9.2 Proof of Proposition 2
Multi-step Discrete Case
Again, we start with the discrete case. Let fig ,ig+1(x) be the pdf of Xig ,ig+1 2 ≤
g ≤ kj and fs,i2(x;u) is the conditional pdf of [Xs,i2|Xs,i2 ≥ u]. Due to the sojourn
time distribution being discrete, Zim,im+1 = θ
Xim,im+1 for m > 2 and Zs,i2 = θ
Xs,i2 (u)
for m = 1.
Take any of the possible sample path: {s, i2, ..., ikj , K+1}. The discounted reward
random variable can be calculated in exactly the same manner as in the single-step
case. Combining the results for the different paths, we get the overall fixed reward
as
FRD(s;u) =
∑
j
I
(j)
s,i2,··· ,ikj ,K+1Us,i2 (Zs,i2 + Ui2,i3Zs,i2Zi2,i3 + · · ·
+Uikj ,K+1(Zs,i2Zi2,i3 · · ·Zikj ,K+1)
)
.
(2.40)
The same arguments can be used to get the variable reward over the remaining
life of the subject as
(2.41) V RD(s;u) =
∑
j
I
(j)
s,i2,··· ,ikj ,K+1
θ
1− θ
(
Vs +
k∑
g=1
(Vig − Vig+1)
g∏
m=1
Zim,im+1
)
,
where i1 = s and ik+1 = K + 1.
Let Wig ,ig+1 = Uig ,ig+1 +
θ
(1−θ)(Vig+1 − Vig). Combining the fixed and variable
rewards, we get the total discounted random reward as
(2.42) RD(s;u) =
∑
j
I
(j)
s,i2,··· ,ikj ,K+1
(
Vs +
k∑
g=1
[Wig ,ig+1
g∏
m=1
Zim,im+1 ]
)
,
where i1 = s and ik+1 = K+ 1. This proves part (a) of Proposition 2 for the discrete
case.
From the independence of the Xi,j’s, we get the expected discounted reward as
(2.43) E(RD(s;u)) =
∑
j
ps,i2,··· ,ikj ,K+1
(
Vs +
k∑
g=1
[Wig ,ig+1
g∏
m=1
E(Zim,im+1)]
)
.
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Let Lim,im+1(γ) be the Laplace transform of Xim,im+1 for m ≥ 2 and of Xs,i2(u) for
m = 1. Then, E(Zim,im+1) = E(θ
Xim,im+1 ) = Lim,im+1(− log(θ)). This proves part (b)
of Proposition 2 for the discrete case.
Multi-step Continuous Case
The results for the continuous case follow easily from the discrete multi-step case.
Recall that fig ,ig+1(x) is the pdf of Xig ,ig+1 2 ≤ g ≤ kj and fs,i2(x;u) is the conditional
pdf of [Xs,i2|Xs,i2 ≥ u]. Due to the sojourn time distribution being continuous,
Zim,im+1 = exp(−ρXim,im+1) for m > 2 and Zs,i2 = exp(−ρXs,i2(u)) for m = 1.
The discounted random variable for the fixed rewards along a path j has the same
form as in the case with the discrete-time sojourn distribution:
FRuD(s) =
∑
j
I
(j)
s,i2,··· ,ikj ,K+1 (Us,i2Zs,i2 + Ui2,i3Zs,i2Zi2,i3 + · · ·
+Uikj ,K+1(Zs,i2Zi2,i3 · · ·Zikj ,K+1)
)
.
(2.44)
For the variable rewards, the random variable is
(2.45) V RuD(s) =
∑
j
I
(j)
s,i2,··· ,ikj ,K+1
1
ρ
(
Vs +
k∑
g=1
(Vig − Vig+1)
g∏
m=1
Zim,im+1
)
,
where i1 = s and ik+1 = K + 1.
Now, let Wig ,ig+1 = Uig ,ig+1 +
1
ρ
(Vig+1 − Vig). The total discounted random reward
is thus
(2.46) RuD(s) =
∑
j
I
(j)
s,i2,··· ,ikj ,K+1
(
Vs +
k∑
g=1
[Wig ,ig+1
g∏
m=1
Zim,im+1 ]
)
,
This proves part (a) of Proposition 2 for the continuous case.
The expected discounted reward as
(2.47) E(RuD(s)) =
∑
j
p
(j)
s,i2,··· ,ikj ,K+1
(
Vs +
k∑
g=1
[Wig ,ig+1
g∏
m=1
E(Zim,im+1)]
)
.
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Let Lim,im+1(γ) be the Laplace transform of Xim,im+1 for m ≥ 2 and of Xs,i2(u) for
m = 1. Then, E(Zi,j) = E(exp(−ρXim,im+1)) = Lim,im+1(ρ). This proves part (b) of
Proposition 2 for the continuous case.
2.9.3 Variances of the Discounted Rewards
We have thus far ignored the calculation of the discounted reward variance, since
expected value is the normal decision-making criterion in CEA. Nevertheless, the
variance of the discounted rewards can also be calculated analytically, and the general
results are in this section.
One-step Case
Recall that in the case with discrete time, the rewards are discounted by a factor
r per unit time, and θ = 1
(1+r)
. For continuous time, the discount rate is ρ, so the
discount for a time of length x is exp(−ρx). As before, let Wg,g+1 = Ug,g+1 +α(Vg+1−
Vg), where α =
θ
(1−θ) for discrete time and α = 1/ρ for continuous time. Further,
in the discrete case, Zs,s+1 = θ
Xs,s+1(u) and Zm,m+1 = θ
Xm,m+1 for m ≥ s + 1. In
the continuous case, Zs,s+1 = exp(−ρXs,s+1(u)) and Zm,m+1 = exp(−ρXm,m+1) for
m ≥ s+ 1.
After some algebraic manipulations, we get the variance of RuD(s) as
V ar(RD(s;u)) =
K∑
g=s
W 2g,g+1
g∏
m=s
E(Z2m,m+1)
+ 2
K∑
g=s
K∑
n=g+1
Wg,g+1Wn,n+1
g∏
m=s
E(Z2m,m+1)
n∏
`=g+1
E(Z`,`+1)
−
(
K∑
g=s
[Wg,g+1
g∏
m=s
E(Zm,m+1)
)2
.
(2.48)
Let Lm,m+1(γ) be the Laplace transform of Xm,m+1 for m > s and of Xs,s+1(u)
for m = s. Then, E(Zm,m+1) = E(θXm,m+1) = Lm,m+1(− log(θ)), E(Z2m,m+1) =
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Lm,m+1(−2 log(θ)). For the continuous case, E(Zm,m+1) = Lm,m+1(ρ) and E(Z2m,m+1) =
Lm,m+1(2ρ).
Multi-step Case
Call Rj the reward earned on path j and Tj the time-to failure on path j in
the multi-step case, and pj the probability of path j, and suppose there are J total
disease paths. From standard properties of mixture distributions (McLachlan and
Peel, 2000),
(2.49) V ar(R(s;u)) =
J∑
j=1
pj (V ar(Tj) + (E(Tj))2)−
(
J∑
j=1
pjE(Tj)
)2
,
where V ar(Tj) and E(Tj) are calculated as in the single-step case. Additionally
(2.50) V ar(R(s;u)) =
J∑
j=1
pj (V ar(Rj) + (E(Rj))2)−
(
J∑
j=1
pjE(Rj)
)2
.
The variance of R(s;u) can be calculated using this equation and the independence
of the Xig ,ig+1 ’s and is given by
V ar[RuD(s)] =
∑
j
ps,i2,...ikj ,K+1
(
K∑
g=1
W 2ig ,ig+1
g∏
m=1
E(Z2im,im+1)
+ 2
K∑
g=1
K∑
n=g+1
[
Wig ,ig+1Win,in+1
g∏
m=1
E(Z2im,im+1)
n∏
`=g+1
E(Zi`,i`+1)
]
+
(
αVs +
K∑
g=s
[Wig ,ig+1
g∏
m=1
E(Zim,im+1)
)2
−
(∑
j
ps,i2,...ikj ,K+1
(
αVs +
K∑
g=s
[Wig ,ig+1
g∏
m=1
E(Zim,im+1)
))2
.
(2.51)
Where again, let Lim,im+1(γ) be the Laplace transform of Xim,im+1 for m ≥ 2 and
of Xs,i2(u) for m = 1. Then, E(Zim,im+1) = E(θ
Xim,im+1 ) = Lim,im+1(− log(θ)),
E(Z2im,im+1) = Lim,im+1(−2 log(θ)). For the continuous case, E(Zim,im+1) = Lim,im+1(ρ)
and E(Z2im,im+1) = Mim,im+1(2ρ).
CHAPTER III
Modeling Cost-Effectiveness Data for Medical Decision
Making: A Statistical Framework
3.1 Introduction
Cost-effectiveness analysis (CEA) is part of the broad field of comparative ef-
fectiveness analysis for health/medical decision making. CEA is designed to assess
the comparative value of expenditures on different health interventions (Gold et al.,
1996). The conceptual basis is that, for a given level of available resources, the in-
terventions that provide the greatest health value should be selected. As the name
implies, CEA requires a comparison two types of health outputs: cost and effective-
ness.
Cost-effectiveness analyses have been conducted for a variety of treatments in a
range of population for diseases including depression (Valenstein et al., 2001), asthma
(Paltiel et al., 2001), HIV (Long et al., 2006), cardiovascular disease (Liew, 2006;
Rosen et al., 2005), stroke (Matchar et al., 2005), and colorectal cancer (Castelli
et al., 2007). The UK, Australia, and Canada require economic evaluations before
approving new healthcare technologies (Birch and Gafni, 2004; Hill et al., 2000;
Hjelmgren et al., 2001), although CEA is not required before the introduction of
a treatment in the United States. Clearly, there is considerable value for patients,
physicians, and policy-makers in understanding the cost, quality of life, and length
57
58
Figure 3.1: Example Model Disease States and Transitions.
of life tradeoffs inherent in medical decisions. The cost outcome is the cumulative
amount of dollars spent on the subject’s health care due to the intervention, usually
discounted to present-day dollars at start of intervention. Quality and length of
life outcomes are combined to get a single measure called quality-adjusted-life-years
(QALYs). Quality is a weight between 0 and 1 that is assigned to the subject
depending on the health state (such as normal, renal disease, cardiovascular diseases,
etc.). The weight is multiplied by the life-time in that state and accumulated to get
a QALY value, which is also usually discounted to get a present value.
Data on cost and effectiveness of the treatment group and a baseline comparison
group may be obtained from through clinical trials, observational studies, or sim-
ulation. In this paper, we focus on data from discrete event simulation models of
multi-state disease processes. We will use the context of the following application to
illustrate the methods and the usefulness of the analysis in the rest of the paper.
Figure (3.1) represents a simplified version of the model developed in Rosen et al.
(2005) to assess the benefits of angiotensin-converting-enzyme-inhibitors (ACE- in-
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hibitors) for a high-risk group of patients. Rosen et al. (2005) studied the problem
from Medicare’s perspective, with the intervention (treatment 1) being coverage for
beneficiaries with diabetes, and the standard (treatment 0) was standard care, re-
quiring an out-of-pocket co-pay. Figure (3.1) is the model structure for examining
combined effects of the intervention on cardiovascular disease (CVD) and renal dis-
ease. The number of states has been reduced for illustrative purposes. There are two
states of renal disease (mild or no renal disease, and end-stage renal disease (ESRD))
and three CVD states (myocardial infarction or heart attack (MI), cerebrovascular
disease or stroke (CVA), or both MI and CVA). Finally, there is an absorbing state
representing death. There are four possible causes of death in this set up: MI, CVA,
ESRD, and other (independent) causes. Figure (3.1) shows the state space and possi-
ble transitions for this hypothetical example. We will use different sets of illustrative
data to demonstrate the benefits of the various data analysis strategies.
Discrete event simulation (DES) simulates the disease process for a subject from
the population of interest, starting with an initial state and progressing through
the different states over time until death. The costs and QALYs are computed as
the subject evolves through the multi-state process until death. This is done for
both the baseline care as well as the proposed new intervention. The simulation will
be repeated for a large number of subjects with characteristics chosen to represent
the population of interest and with covariates that can vary over time, such as
those representing the health status of the subjects. Throughout this paper, we
assume that the simulation size is large enough to treat the estimated processes and
distributions as continuous.
Most of the commonly used metrics for CEA summarize this extensive amount
of simulation data into simple mean-based measures. Let µj(C) be the average
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(discounted) cost and µj(E) be the average (discounted) effectiveness (QALYs) for
treatment j, j = 0, 1. Here treatment 0 is the baseline and treatment 1 is the new
treatment. (There can be more than one new treatment being compared, but we
restrict to just one for simplicity). The cost and effectiveness are usually computed
over the entire remaining life span of the subjects or some fixed long horizon such
as 30 years. Then, the metrics used for comparison are based on the differences
in means: µ1(C) − µ0(C) and µ1(E) − µ0(E). The most common one-dimensional
measure is the incremental cost-effectiveness ratio (ICER)
(3.1) µICER =
µ1(C)− µ0(C)
µ1(E)− µ0(E) .
Another commonly used metric is the Net Monetary Benefit (NMB)
(3.2) µNMB = λ [µ1(E)− µ0(E)]− [µ1(C)− µ0(C)] ,
where λ measures society’s willingness to pay for one QALY. These and other com-
monly used metrics for CEA are traditionally based on expected values or averages.
One justification for using average cost is that, from a decision-making perspective,
it is the total cost of the intervention that matters. But the analogous justification
for using average effectiveness is less compelling.
Such simple metrics are popular because they are simple and easy to understand
by high-level policy decision makers. However, like all such summaries, they are
overly simplistic and do not provide sufficient insights into the complex data, which is
time-varying and heterogeneous, and into the trade-offs between cost and benefits. In
fact, there has been debate in the literature to the extent to which cost-effectiveness
ratios are appropriate for informing medical decisions (Birch and Gafni, 1992; Garber
and Phelps, 1997; Sendi et al., 2003; Weinstein et al., 2001).
Our goal in this paper is to demonstrate the usefulness of using graphical methods
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to analyze the simulation data more extensively and develop key insights into the
performance of the treatments and their comparisons. The salient aspects of the
simulation data can be summarized easily in simple cases such as Markov models.
In more realistic situations, such as non-homogeneous processes, the data can have
complex structure even though they are just realizations of simulated processes with
known inputs.
The distribution of costs and benefits associated with an intervention is a result
of randomness and differences in the underlying population, both in terms of clinical
indicators and personal preferences (Stevens and Normand, 2004; Sculpher and Gafni,
2001). McMahon et al. (2005) commented on the differences in outcomes and CE
ratios in heterogeneous patients, and how clinical trials often show the most benefits
from interventions are concentrated in the highest-risk patients (Vijan et al., 1997;
Kent et al., 2002). There is a lot of information to be gleaned from examining the
entire distribution, examining it for heterogeneity, multi-modes, tail behavior, etc.
These are all important sources of information for the research investigator about the
behavior of the treatment and its comparison to the baseline. Before a final policy
decision is made, it is incumbent upon the researcher to systematically scrutinize the
underlying data, examine different features both visually and analytically, develop
insights about the properties of the intervention over time and across groups of
patients, and use all the information before making overall recommendations and
decisions. Of course, experienced clinicians and researchers will have considerable
insights even before the simulation study is conducted, but even they will get new
information from the analysis. Of course, there will be others, including the decision
makers, for whom the analysis will be very useful in understanding the reasons for
and the trade-offs involved in the ultimate decision.
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The paper is organized as follows. Section 3.2 introduces and discusses the
stochastic disease process. Section 3.2.2 discusses the stochastic reward processes
derived from the disease process. Section 3.3 applies the stochastic process frame-
work and applies graphical methods for exploratory data analysis to hypothetical
CEA simulation results.
3.2 Disease Progression Model
In this section, we develop some terminology and notation to characterize the
underlying stochastic processes that are being simulated.
3.2.1 Disease Process
We will use a multi-state model (as in Figure (3.1)) to characterize the disease
process: how the subject evolves through the various disease states until death. Let
{Yj(t), t ∈ T } denote the state of the subject at time t for t ∈ T for treatments
j = 0, 1. Time t can be discrete in which case T is the set of nonnegative integers
{0, 1, 2, ...K+ 1} or continuous in which case T is the non-negative half-line {t ≥ 0}.
The process {Yj(t)} takes values in the finite state space E = {1, 2, . . . , (K + 1)},
which are the various states of health status. We take (K+1) to be an absorbing state
or end point of the process, denoted as ‘failure.’ In the context of CEA problems,
this state will typically be death. Subjects can start the simulation in different initial
states and they will have been in the state for different periods of time, and may
have different ages. There are also important covariates that will distinguish different
subjects. We will ignore these important points for the time being come back to them
later in the discussion.
There has to be some specification of the underlying probabilistic mechanism that
generates the transitions and the sojourn times. For our purposes here, we assume
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that they are specified in setting up the simulation study and reasonable estimates of
the underlying parameters are available from the literature of field studies. We will
also not focus on sensitivity to the estimated values, as this problem has received
substantial attention in the literature (Hunink et al., 1998; Halpern et al., 2000).
There are analytical approaches to studying the behavior of multi-state processes
in simple cases: Markov processes and semi-Markov processes and more general time-
homogeneous processes (see, for example, Howard (1971) and Janssen and Manca
(2006)). We will assume that the processes being studied here are more complex and
so a discrete event simulation study is used.
There are several random variables of interest associated with the disease process.
Perhaps the most important one is the time-to-failure Tj, the time t when the process
Yj(t) reaches the absorbing state K + 1. Throughout, we denote the cumulative
distribution function (CDF) of Tj as Fj(t;T ), t ∈ T and the corresponding quantile
functions as Qj(u;T ) = F
−1
j (u), u ∈ (0, 1). Further, the mean or expected time-
to-failure will be denoted as µj(T ) and the hazard rate as hj(t;T ) for j = 0, 1. In
general, the Fj’s are a mixture distribution and their expressions cannot be obtained
analytically, even for Markov and semi-Markov processes (see Aalen (1995), DeFauw
et al. (2011) and Yang and Nair (2011)). But the simulation data will allow us
to study their properties and make comparisons, based on means, quantiles, tail
behavior, hazard rate, etc.
3.2.2 Cost, Effectiveness and Other Derived Processes
As subjects evolve through the disease process, they accumulate costs and QALYs.
The particular structure of these, especially costs, will depend on the application.
For example, there can be an immediate cost associated with a transition from state
i to state j (for example, surgery for an MI) and there can be costs per unit time
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spent in state j (such as cost of long term medical care). These issues are discussed
in general terms under reward processes in Howard (1971) and Janssen and Manca
(2006). See also DeFauw et al. (2011).
We will use the notation {Cj(t), t ∈ T } and {Ej(t), t ∈ T } to denote the cumu-
lative cost and reward processes: so, Cj(t) is the cumulative cost and Ej(t) is the
cumulative effectiveness for treatment j up to time t, for j = 0, 1. These processes
may or may not have been discounted, depending on the application. Further, we
let Fj(x; t;C) = P (Cj(t) ≤ x) denote the CDF of the cost process at time t and
its quantile function as Qj(u; t;C) = F
−1
j (x; t;C) with similar definitions for effec-
tiveness: Fj(u; t;E) and Qj(u; t;E). The means of the corresponding distributions
will be denoted as µj(t;C) and µj(t;E). The end of the study will correspond to
t =∞ (when all the subjects have died) or more likely, a large value of t. Analytical
expressions for the cost and effectiveness processes and their means were developed
in DeFauw et al. (2011) for the case of progressive, time-homogeneous semi-Markov
processes. Reference Janssen and Manca (2006) and Janssen and Manca (2007) for
a general discussion of reward processes. Again, the simulation data will allow us
to study the behavior of these quantities and interpret their behavior from CEA
perspective, as to be discussed.
Sometimes, the notions of incremental cost and effectiveness processes are useful.
For example, for chronic diseases where patients live with for many years, studying
incremental annual costs and seeing how they vary over time makes sense. In the
case of more short-term, acute, or rapidly advancing diseases, weekly or daily repre-
sentation of incremental processes may be more useful. We will define incremental
cost as cj(t) = Cj(t)−Cj(t−δ) and incremental effectiveness ej(t) = Ej(t)−Ej(t−δ)
for some suitable time period δ. For discrete processes, δ will typically be 1.
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Another derived process of interest is the cumulative monetary benefit (MB) pro-
cess which is defined for treatment j at time t as Bj(t) = λEj(t) +Cj(t) for j = 0, 1.
We let Fj(u; t;B) = P (Bj(t) ≤ x) be the CDF of the MB process at time t and
its quantile function as Qj(u; t;B) = F
−1
j (x; t;B) The means of the corresponding
distributions will be denoted as µj(t;B) and µj(t;E). Recall that the usual NMB
is given by µ1(∞, B) − µ0(∞, B). As with the other cases, we define incremental
monetary benefit as bj(t) = Bj(t)−Bj(t− δ) for some suitable time period δ.
3.3 Richer Analysis: Illustrative Examples
This section will rely primarily on graphical methods to illustrate the potential
in exploring the simulation data in more detail. There is an extensive literature on
graphical methods, and some good references include Chambers (1983) and Cleveland
(1993). See also Doksum and Sievers (1976) for a discussion of treatment-effect
functions. Throughout, we are assuming that the number of simulations is very
large so that, for all practical purposes, the distributions are assumed to be known.
3.3.1 Exploratory Analysis for Interesting Features
There are many graphical techniques for visually examining the data when the
sample sizes are small to moderate. These include boxplots, stem-and-leaf-diagrams
and histograms. Sample sizes in the kinds of simulation studies considered here will
be quite large, and we use a density plot (smoothed histogram) to examine features
of the data.
Consider first cost and effectiveness outcomes at the end of the study. The left
panel in Figure (3.2) shows illustrative densities for treatment and standard: effec-
tiveness data in the right panel and cost data in the left panel. Both cost distributions
are skewed with heavy right tails. This is typical of cost outcomes (just as is the case
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with income distributions), indicating that a small proportion of the population con-
tributes most to the total cost. The tails will have an undue influence on the mean,
so mean-based comparisons can be unduly affected. More importantly, relying on
just simple metrics for comparison can result in the loss of very useful information.
The cost distribution for the standard treatment has a heavier right tail than the
new treatment, and it would be of interest to explore the reasons for this difference.
Suppose we took a deeper look at the percentage of costs incurred by patients in
the highest 20% of each cost distribution, leading to Figure (3.3). We see that a
disproportionate amount of the costs in the right tail for the standard treatment are
incurred by patients in the ESRD state. The treatment is very effective in reducing
this part of the costs.
Figure 3.2: Left: Effectiveness Distributions. Right : Cost Distributions.
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Figure 3.3: Percentage of Cost from Each State.
Consider now the left panel in Figure (3.2) which shows effectiveness distributions.
We see that the density under treatment 0 is bimodal, with a smaller mode in the
right tail. This is not the case for treatment 1. Multi-modality is often an indication
of a mixture phenomenon, suggesting differential effects on the population. Suppose
we drill down into the distribution to examine the reasons for the bimodality and find
that the reason is due to differences in income levels of the patients (socioeconomic
status, or SES). Specifically, a significant portion of the high-income patients were
already taking ACE-inhibitors, so the policy of covering them under Medicare did
not affect their health status. This is confirmed in Figure (3.4) which shows a
substantial difference between the two populations under treatment 0, and shows
that the patients in the high SES group have a distribution similar to the distribution
of the entire population under treatment 1. This group formed only about 25% of
the overall population, so the difference between the groups showed up only slightly
in Figure (3.2). Of course, in a simulation study, this information is part of the
input parameters and so is already known. However, the effects of different input
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Figure 3.4: Left: Effectiveness Distribution of Treatment 0, Stratified by SES.
parameters may not be easily discerned up front. Moreover, the effects could be off-
set by other factors, so there is considerable value in examining the data to determine
the final outcomes and dig down to understand the reasons. In this example, there
are several possible consequences to the finding: a) one could consider the option
of not providing coverage for high-income patients if this is feasible; and b) the
effectiveness of the treatment in the remaining population is much bigger than a
simple mean-based comparison would suggest.
3.3.2 Comparing the Difference in Distributions Using Q-Q plots
The densities are useful in highlighting certain aspects of the distributions (cen-
ter, spread, tails, unusual features, etc.) but are not as effective in comparing the
differences between distributions. In this section, we consider comparisons of CDFs.
The case where the effect of the treatment is to simply shift the response by a con-
stant value ∆ is shown in the left panel of Figure (3.5). This corresponds to shift
distributions where F1(x) = F0(x−∆), or equivalently Q1(u)−Q0(u) = ∆, i.e., the
difference in every u − th quantile is constant. Since ∫ 1
0
Qj(u) du = µj, the mean,
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it also implies that the differences in means equal ∆. In this case, ∆ measures the
treatment effect in a reasonable sense.
Figure 3.5: Left: Shift distribution treatment effect. Right : Uneven treatment effect.
Suppose F1 is entirely below F0, i.e., F1(x) ≤ F0(x) for all x (with strict inequality
for some x), as is the case in the left panel of Figure (3.5). Then treatment 1 is said
to stochastically dominate the other in terms of first order (first-order stochastic
dominance or FSD). Note that F1(x) ≤ F0(x) means that larger values are likely
under F1 compared to F0. Perhaps an easier way of thinking about this is in terms
of the quantile functions: Q1(u) ≥ Q0(u). If the outcome is effectiveness, then
treatment 1 is preferable under FSD, but the opposite is true for cost.
But the treatment effect is likely to be more complex in practice, and we need ways
to interpret them. In general, the distributions will cross (as in the right panel of
Figure (3.5)), indicating that treatment 1 is better than treatment 0 in one region but
not the other. It is difficult to assess the magnitude of the differences between CDFs
as both are curves. For this reason, statisticians have proposed plotting the quantiles
against each other: Q0(u) on the horizontal axis and Q1(u) on the vertical axis
(see Figure (3.6)). This is called the quantile-quantile or Q-Q plot in the statistics
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Figure 3.6: Quantile-Quantile Plot.
literature. The effect of this plot is to transform the y-axis from a probability scale
to a quantile scale.
There are a number of visual advantages with the Q-Q plot. If the two distri-
butions are identical, the plot will fall on the identity line. If the location model
F1(x) = F0(x−∆) holds, (effect of the treatment is to just change the outcome by ∆
at all values), the plot will be linear with slope 1 and intercept ∆. It is much easier to
determine such an effect from this graph than from the plot of the two CDFs in Fig-
ure (3.5). More generally, if a location-scale model holds, i.e., F1(x) = F0([x− a]/b)
for some constants a and b > 0, the plot will still be linear, but with slope b and
intercept a. It is unlikely that a location-scale model will hold for outcomes such
as failure times, costs and effectiveness, which are constrained to be non-negative.
However, it is common in statistical analysis to take the logarithm of the data and
then do a Q-Q plot to compare the distributions. For example, distributions such as
log-normal and Weibull have a location-scale property in the log-scale.
Let ∆(u) = Q1(u)−Q0(u) be the difference of the Q-Q plot (Q0(u), Q1(u)) from
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the identity function. We will refer to this as the treatment-effect function. (Dok-
sum and Sievers (1976) referred to this as a response function but used a slightly
different form: θ(x) = Q1(F0(x)) − x, which equals ∆(F0(x)).) This treatment-
effect function captures the difference in the treatments in different regions (quan-
tiles) of the distributions. For example, the difference in medians is ∆(.5) and∫ 1
0
∆(u) du =
∫ 1
0
[Q1(u)−Q0(u)] du = µ1 − µ0, the difference in means.
Figure 3.7: Left: Q-Q Plot of Effectiveness Distributions. Right : The treatment-effect, ∆(u), for
Effectiveness.
Figure (3.7) shows an illustrative example for a (hypothetical) intervention for
cardiovascular and heart disease, different from ACE-inhibitor example already used.
The left panel is a Q-Q plot of effectiveness distributions and the right panel shows the
treatment-effect function ∆(u;E). An examination of this function shows that the
treatment is slightly harmful, compared to the standard, in the lower tail but is quite
effective in the other regions. The natural next step is to dig into possible reasons
for this behavior. Figure (3.8) shows a bar plot of the patients in the lower 30% of
the treatment 1 effectiveness distribution and the overall population, classified by
the two relevant racial groups for this example: Caucasians and African-Americans.
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We see that there is a disproportionately higher portion of African-Americans in the
lower tail of treatment 1, suggesting that the treatment is harmful to this group.
Again, such a finding will have important consequences for the decision makers and
would not have been discovered in a simple mean-based comparison.
Figure 3.8: Weight Classification of Patients in Lower Quantiles of Effectiveness Distributions.
Figure 3.9: Left: Q-Q Plot of Cost Distributions. Right : ∆(u) of the Cost Distributions.
Consider a different example. Figure (3.9) compares the cost distributions of two
hypothetical treatments, and we see that ∆(u;C) > 0 at the low quantiles with
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the situation reversed at the higher quantiles. Suppose further analysis to identify
the reasons for the differences leads to Figure 3.10: the left panel shows Q-Q plot
for patients who were healthy at the start of the study and right panel shows Q-Q
plot for patients whose initial state was ESRD. The plot in the left panel looks very
similar to that of the overall population in Figure (3.9). On the other hand, ∆(u;C)
is always negative in the right panel, with the function increasing towards the right
tail. This is another example of effect heterogeneity, this time caused by differences
in initial states. Again, this type of information may be obvious to an experienced
investigator, who may know that the analysis should be separated by initial states.
But there are many possible ways to stratify the data, and an analysis such as the one
proposed in the paper suggests ways to systematically explore the data to identify
differences and then dig deeper to determine possible reasons.
Figure 3.10: Left: Q-Q Plot of Cost Distributions for Patients Starting in Healthy State. Right :
Q-Q Plot of Cost Distributions for Patients Starting with ESRD.
Continuing with the same example, one might want to examine the effect of the
stratification for the corresponding effectiveness distributions. Figure 3.11 shows an
illustrative situation. The right panel suggests that the difference in effectiveness
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distributions is negligible for subjects starting in the ESRD initial state. The left
panel indicates that the difference is much more substantial for subjects starting in
the healthy state. We can now close the loop on this story: the treatment is not
effective for patients who already had ESRD and the added cost is due to cost of
the treatment. One obvious conclusion is to not use this treatment for patients with
ESRD. Again, we reiterate that such a conclusion may already be known to (or at
least suspected by) clinicians before the study, but we are using a simple example
such as this to illustrate that similar benefits may arise in more subtle situations.
Figure 3.11: Left: Q-Q Plot of Effectiveness Distributions for Patients Starting in Healthy State.
Right : Q-Q Plot of Effectiveness Distributions for Patients Starting with ESRD.
3.3.3 Comparisons Over Time
We have focused thus far on analyzing data at the end of the study – either when
all subjects in the simulation have died or after a fixed period. This is also the
focus of CEA. Nevertheless, it is of interest to see how the cost and effectiveness
distributions evolve over time, for budgetary or ethical reasons, or to develop further
insights into the treatment effect.
We revisit the examples in Figure (3.2) where the effectiveness distribution at the
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end of the study was bimodal. Figure (3.12) shows this distribution at three different
time points: t = 5, t = 20 and at the end of the study. it shows that the distribution
was unimodal at an early stage but started to develop the bimodal behavior by t = 20
and it became more pronounced by the end of the study. Depending on the particular
intervention, this could again have policy implications or affect the delivery of the
intervention.
Figure 3.12: Left: Effectiveness Distribution at t=5. Center: Effectiveness Distribution at t=20.
Right: Effectiveness Distribution at t=30.
It can be tedious to compare the density functions or Q-Q plots at many different
times; further, it may be difficult to spot small differences. An alternative approach
to analyzing the evolution of reward over time is to plot selected quantiles of the
reward (cost or effectiveness) distributions against time. Figure (3.13) shows the
evolution of the quantiles over time for a pair of hypothetical treatments 0 and 1. It
shows clearly that the variability of the rewards is low in the early part of the study
for both treatments. As time progresses, the variability in the reward gets higher
for treatment 1 than treatment 0, and the pattern is consistent. Figure (3.14) shows
how the treatment-effect function, ∆(u; t) = Q1(u; t)−Q0(u; t) varies with time. In
contrast, Figure (3.15) shows a different shape for ∆(u; t), where the treatment-effect
is zero for large values of u and positive for smaller values.
We make an important, cautionary note in trying to interpret the treatment-
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effect function. The characteristics of the subjects who are in the lower (or upper)
quantiles of Treatment 0 may not be the same as those who are in the corresponding
quantiles of Treatment 1, and these could also change over time. This complicates
the interpretation, and one has to dig deeper into the data to understand possible
reasons in terms of patient characteristics.
Figure 3.13: Left: Quantile functions over time for Treatment 0; Quantiles. Right : Quantile
functions over time for Treatment 1.
Figure 3.14: Treatment Effect Function Over Time,∆(u; t)Q1(p;E; t)−Q0(p;E; t).
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Figure 3.15: Treatment Effect Function Over Time, Q1(u;E; t)−Q0(u;E; t).
3.3.4 Generalized ICER and NMB Metrics
The notion of the treatment-effect function suggests an obvious way to extend the
definitions of ICER and NMB metrics and conduct a more detailed CEA. Define the
ICER function
(3.3) ICER(u; t) =
∆(u; t;C)
∆(u; t;E)
,
the ratio of the treatment-effectiveness functions for cost and effectiveness. This
metric allows one to examine how the ICER metric varies with the quantiles (for
fixed t) and varies with time (for fixed u). Similarly, we can define an NMB function
as
(3.4) NMB(u; t) = λ∆(u; t;E)−∆(u; t;C).
Figure 3.16 shows an illustrative example with the ICER function on the left and
NMB function on the right. Notice that there is huge variability in the ICER function
early on but it stabilizes over time. Also, the quantiles cross, showing an inconsistent
behavior over time.
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Figure 3.16: Left: ICER(u; t). Right : NMB(u; t).
3.3.5 Analysis of Time-to-Failure Data
While the reward processes are of primary interest in CEA, analysis of the time-
to-failure data would also be of interest. We provide some illustrative examples
here.
If an intervention is considered effective, it would normally be expected to increase
the length of life, on average. The increased lifespan my arise in a number of ways.
First, a treatment may not change disease progression (the health states a patient
experiences), but slow it down (increase the time spent in each health state). If this is
true, the treatment effect on the time in health states may be the same for all health
states (i.e., treatment increases the time in each health state by 25%). Alternatively,
it may slow disease progression unequally in each health state. A second way a
treatment might act is my changing the disease progression entirely. In the case of
a multi-state model, this would mean that the treatment would actually alter the
probabilities of a patient experiencing or dying from a given medical event. As an
example, a treatment may lower the lifetime probability of a patient experiencing an
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MI.
In a multi-state disease process, understanding the time spent in each state can
also provide insight into the drivers of the difference between the two treatments.
Figure (3.17) shows this comparison for the Medicare coverage of ACE-inhibitors in-
tervention (treatment 1), versus the baseline (treatment 0). The side-by-side barplot
shows that patients receiving treatment 1 live longer, and spend much more time in
the healthy state. Additionally, patients receiving treatment 0 spend more time in
all states containing ESRD. This tells the decision-maker that on average, treatment
1 helps patients avoid time in ESRD states and remain healthier, longer, than those
receiving treatment 0.
Figure 3.17: Time in Each State.
A difference in disease progression may also indicate a difference in the modes of
death. Figure (3.18) shows the percentage of deaths due to each of the 4 possible
causes: MI, CVA, ESRD, and competing risk causes (causes not included in the
model). If the figure had bars of equal height for treatment 1 and treatment 0,
that would indicate that the treatment does not effect the mode of patient death.
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However, this is not the case in this example. Figure (3.18) shows that, relative to
treatment 0, patients receiving treatment 1 are less likely to die of CVA and ESRD,
but are more likely to die of MI or competing risk causes. This suggests that, relative
to treatment 0, treatment 1 reduces CVA and ESRD. However, it does not have a
fully protective effect against all CVD, since MI death is comparatively more likely
under treatment 1.
Figure 3.18: Mode of Death.
As we have already seen, stratification of patients by the health state at the start of
treatment can provide useful insight into the differences in death mode. Figure (3.19)
shows the proportions of subjects in each death mode, conditional upon patient
health state at the start of treatment. There is a large difference that depends upon
patient’s initial health. In the case of patients with a history of MI, CVA, or renal
disease, it is very common for the patient to die of whatever complication they have
a history of, regardless of treatment. Patients beginning with no history of renal
disease or CVD are relatively unlikely to die of CVD or renal disease complications,
and more likely to die of competing risk causes.
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Figure 3.19: Top Left: Death Mode for those Starting Healthy. Top Right : Death Mode for those
Starting with an MI. Bottom Left: Death Mode for those Starting with a CVA. Bottom Right :
Death Mode for those Starting with Renal Disease.
3.4 Conclusion
The paper has demonstrated the usefulness of exploring the data from simulation
studies more fully, instead of just relying on simple CEA. We have used hypothet-
ical, illustrative examples in our demonstration, which are by necessity too simple.
Nevertheless, we hope that we have been successful in showing the benefits of such
an approach.
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We have not discussed methods for examining the effects of covariates, such as
other indicators of health-status, in this paper. The effect of time-varying covariates,
in particular, can be difficult to predict. These can be handled through regression
or other types of analyses, suitably modified for the type of data.
CHAPTER IV
Quantifying Treatment Effect in Cost-Effectiveness Analysis
4.1 Introduction
There is growing emphasis in the healthcare area on containing costs while also
improving treatment effectiveness (health gained from treatment). The main goal of
cost-effectiveness analysis (CEA), which uses metrics based on costs and effectiveness
to assess and compare interventions, is to identify effective treatments while also lim-
iting healthcare expenditures. One or more new interventions are compared against
the current or baseline intervention. The term intervention is used to characterize a
variety of options: screening strategies, pharmaceutical treatments, diagnostic tools,
surgical treatments, etc., and they may be implemented via policy- or payer-level
requirements or incentives.
While there are several ways to measure effectiveness of a treatment, quality-
adjusted-life-years (QALYs) are the most common. Both costs and QALYs are usu-
ally discounted at some rate to bring the values at different times to a common
reference value. Discounting QALYs is less intuitive than discounting cost, but CEA
relies on the assumption that QALYs have a monetary value, and also that there is
a constant trade-off between costs and QALYs.
There is a huge literature on the development and use of various metrics for CEA.
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Most of them are based on the means of the (random) cost and effectiveness outcomes,
where the expected values are taken with respect to some population of interest. We
review the commonly used metrics in the next section. There has been some effort
to go beyond mean-based analysis in the CEA literature, although this is relatively
limited. We discuss the notions of first and second-order stochastic dominance (FSD
and SSD) of the distributions and discuss their usefulness in CEA. SD concepts are
well known in economics and finance but their use in healthcare decision making
has not received much attention (see Laska et al. (1999); Leshno and Levy (2004) for
some exceptions). Notions of almost stochastic dominance (ASD) from the literature
are also discussed. Even when a new treatment does not stochastically dominate the
current one (as will be the case in many situations), it is of interest to examine
regions of the outcomes space where the new treatment is better than the standard.
Such insights will allow the decision-maker to make more informed decisions.
The concepts of FSD and SSD are popular in economics and finance in part
due to their relationships to general classes of utility functions. We also consider
comparisons in terms of more specialized, parametric utility functions.
A second, and bigger, focus of the paper is CEA in the presence of statistical
uncertainty. In practice, the metrics used for comparison have to be estimated from
field data, inducing estimation uncertainty which has to be taken into account in the
comparisons. We review selected, important results in the CEA literature for mean-
based comparisons: using both large-sample normal approximations and resampling
methods. While these methods are applications of well known results in the statis-
tical literature, there appears to be some confusion that we review and clarify. We
also propose the use of rank-based methods and discuss analysis of censored and
paired comparison data. The new contributions to the CEA literature include SD
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comparisons in the presence of statistical uncertainty.
The rest of the paper is organized as follows. In Section 4.2, we describe the
common mean-based metrics for CEA. Section 4.3 reviews methods for comparisons
based on these metrics in the presence of statistical uncertainty and proposes the
use of other methods from the statistics literature to CEA; these include use of
rank-based methods and analysis of censored data. In Section 4.4 we expand the
comparisons to include utility functions and examining the entire distributions. The
role of utility functions is discussed in Section 4.4.1 and the application of first- and
second-order stochastic dominance in CEA is the subject of Section 4.4.2. This is
followed by the consideration of stochastic dominance comparisons in the presence
of uncertainty. Throughout the paper, we demonstrate concepts using illustrative
examples.
4.2 Mean-Based Metrics for CEA Analysis
Suppose we are comparing a new intervention (treatment 1) against a current or
baseline intervention (treatment 0). Let Cj and Ej, j = 0, 1 be the (random) cost and
effectiveness outcomes over some appropriate lifetime of a subject. Further, there is
some underlying population of subjects that is of interest (such as all patients eligible
for Medicare, patients who are at risk of a disease, etc.). These specifics will depend
on the particular application, and for the purposes here, we assume that they have
already been well formulated.
Let Fj(t;C) and Fj(t;E) be the cumulative distribution functions (CDFs) of Cj
and Ej respectively, for j = 0, 1. Denote by µj(C) and µj(E) their expected values,
i.e., mean cost and mean effectiveness measures. Define ∆(C) = µ1(C)− µ0(C) and
∆(E) = µ1(E)−µ0(E) be the differences in costs and effectiveness respectively. Most
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Figure 4.1: Cost-Effectiveness Plane.
of the metrics in the CEA literature are based on these means – more specifically on
the differences ∆(C) and ∆(E).
Direct two-dimensional analyses have been proposed in the literature (O’Brien
et al., 1994). Here, ∆C and ∆E are plotted on the x- and y-axes separately (see
Figure (4.1)). If the values fall in the lower right quadrant, the new treatment is more
effective and has lower cost than the baseline treatment (termed “dominance” in the
CEA literature). If they fall in the upper left quadrant, the baseline treatment has
higher effectiveness and lower cost. There is a trade-off between cost and effectiveness
if the values fall in the upper right or lower left quadrants. In those quadrants, a
intervention is considered cost-effective if it lies below the line through the origin
with slope λ, the value of the decision-makers willingness-to-pay.
There are several metrics in the literature for combining the two-dimensional
information on costs and effectiveness into a single metric. Perhaps the most common
one is the incremental cost-effectiveness ratio (ICER) given by
µICER =
µ1(C)− µ0(C)
µ1(E)− µ0(E) =
∆(C)
∆(E)
.
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µICER is compared against a value λ, the amount of money that society is willing to
pay for a single unit of effectiveness. We can think of λ as the factor used to convert
effectiveness into the same scale as cost. If µICER is less than λ (and ∆(E) > 0), then
the new treatment is deemed cost-effective. If not, then the current treatment is
more cost-effective. The willingness-to-pay value is represented in Figure (4.1) with
a dashed line. See O’Brien et al. (1994) for more details.
An assessment of the two treatments in terms of µICER can be visualized in the
two-dimensional plot in Figure (4.1) as follows. Consider the line with slope λ in the
figure. A new intervention is considered cost-effective compared to the baseline, in
terms of ICER, if the point (∆(E), ∆(C)) falls to the right of this line.
Any one-dimensional summary, such as the ICER, will naturally result in a loss of
information. For example, a negative ICER may be caused by the numerator or the
denominator being negative, and the interpretations are quite different – the new
intervention results in higher costs and is less effective or lower costs and greater
effectiveness (Stinnett and Mullahy, 1998). The ICER is known to have additional
disadvantages. If the difference in effectiveness ∆(E) is close to zero, µICER can
be very large. These problems are exacerbated when the ICER metric is estimated
from sample data. It can have huge variability if the true value ∆(E) is close to zero.
Moreover, the signs of the estimates can get switched. Some authors have proposed
a two-phase approach – first determining if ∆(E) is positive (treatment 1 is better
in terms of effectiveness) and then seeing if the ICER metric is positive and what
its value is. This is of course equivalent to a two-dimensional analysis and does not
really mitigate the problems.
Stinnett and Mullahy (1998) proposed two (equivalent) alternatives called Net
Health Benefit (NHB) and Net Monetary Benefit (NMB). To define these, define a
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random variable called monetary benefit (MB) of treatment j as
(4.1) MBj = λEj − Cj, j = 0, 1,
where, as before, λ is used to convert effectiveness into its monetary equivalent.
Then, NMB is defined as
(4.2)
µNMB(λ) = E(MB1−MB0) = λ[µ1(E)−µ0(E)]− [µ1(C)−µ0(C)] = λ∆(E)−∆(C).
If the monetary equivalent of the effectiveness is greater than the cost of the treat-
ment, NMB will be positive and the new treatment is preferred. Otherwise, the
current treatment is preferred. Similarly, NHB is defined as
(4.3) µNHB(λ) = ∆(E)−∆(C)/λ.
Since NMB and NHB are equivalent, we will focus on NMB only in the rest of this
paper. Note the one-to-one relationship: µICER = λ if and only if µNMB(λ) = 0. We
will return to this connection later in the paper.
We note for use later in the paper that NMB is linear in all of its terms, and can
be rewritten as
µNMB(λ) = (λµ1(E)− µ1C)− (λµ0(E)− µ0C)
= µ1(MB)− µ0(MB),
(4.4)
where µ1(MB) = λµ1(E) − µ1C, and as such is the mean monetary benefit of
treatment 1 (i.e., the mean weighted combination of costs and effectiveness resulting
from treatment 1). µ0(MB) has an analogous definition, and is the mean monetary
benefit of treatment 0. If µ1(MB) > µ0(MB), then µNMB > 0, and this relationship
allows us to determine the significance of µNMB by comparing the means of the two
samples.
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Since NMB is also a one-dimensional reduction, it loses important information.
For example, if it is positive, all we know it that λ∆(E) > ∆(C); similarly if it is
negative λ∆(E) < ∆(C).
Another alternative, proposed by Laska et al. (1997) is the difference in cost-
effectiveness ratios (DCER):
(4.5) µDCER =
µ1(C)
µ1(E)
− µ0(C)
µ0(E)
.
Note that this metric is not a function of just the differences ∆(E) and ∆(C), so
it does not suffer from problems of ∆(E) being close to zero, like the ICER. How-
ever, this metric has been criticized by Briggs et al. (2007) who note that economic
decisions should be made based on the marginal difference between an option and
the next-best comparator, which is accomplished using µICER. Therefore, we will not
consider it further in this paper.
We make some final comments about the mean-based metrics before moving to
estimation uncertainty. Note that, if the underlying distributions are symmetric, the
mean coincides with the median, so these metrics can also be viewed as comparisons
of differences in medians, There are other cases also where the differences in the
means coincide with the differences in medians. Suppose F1(t;C) = F0(t−ηC;C) and
F1(t;E) = F0(t− ηE;E), i.e., a location (or shift) model holds. Then, the differences
in means, medians and other location parameters coincide with the differences in the
location parameters ηC and ηE. One consequence is that we can use other estimators
besides the sample means to estimate the differences. This will be taken up later in
the paper.
In practice, however, the treatment difference will be complex, affecting the dis-
persion and other aspects of the distribution. The focus on means for CEA inference
comes from an economic perspective (Briggs and Gray, 1998; Thompson and Bar-
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Figure 4.2: Monetary Benefit Distributions.
ber, 2000; O’Hagan and Stevens, 2002). This certainly makes sense for cost as the
decision-maker would be very interested in the differences in total (expected) costs
of the two treatments. It is less compelling for effectiveness and MB, where there
are important ethical considerations. If the distribution of effectiveness or MB out-
comes is highly skewed, the median is a more appropriate singe-number summary
than the mean. For example, consider the two distributions (F1 corresponding to
treatment 1 and F0 corresponding to baseline) in Figure (4.2). The expected value
of the new treatment is 39, 400 and the standard is 25, 000, so the new treatment
is better in terms of mean. But a comparison of the two CDFs in the figure shows
that the standard distribution is better than the new treatment even up to the 75-th
percentile.
We discuss some alternatives to mean-based comparisons later in the paper. These
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include median of the differences in treatments and comparisons in terms of utility
functions and stochastic dominance.
4.3 Incorporating Statistical Uncertainty with Mean-Based Metrics
As noted earlier, the actual mean values required for CEA analysis are not known
in practice. Rather, they are estimated from data, typically from clinical trials (see,
for example Meenan et al. (1998), van Hout et al. (1994), and Kinlay et al. (1996)).
The estimation of the parameters induces uncertainty which can be substantial when
the sample sizes are small to moderate, so this must be incorporated in the compar-
isons. This topic has been considered by many authors in the CEA literature. We
provide a review and critical assessments of the key methods.
We first consider the situation where the field data are uncensored, the only case
that appears to have been considered in the CEA literature. Extensions to censored
data will be described at the end of this section.
Suppose we have data on n0 subjects for the baseline treatment and n1 subjects
for the new treatment. Typically n0 will be larger than n1, although this is not
an important issue for our purposes here. We assume the data from the different
subjects are independent and identically distributed from the corresponding cost and
effectiveness distributions. Let µˆj(C) and µˆj(E), j = 0, 1, be the sample averages of
the observed costs and effectiveness values. Further, let ∆̂(C) = µˆ1(C)− µˆ0(C) and
∆̂(E) = µˆ1(E)− µˆ0(E)
Then, we can define the corresponding estimated quantities as
µˆICER =
∆̂(C)
∆̂(E)
,
and
µˆNMB(λ) = λ∆̂(E)− ∆̂(C).
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We also need notation for the variances and their estimators. Let Vj(C) be the
variance µˆj(C) and Vj(E) be the variance of µˆj(E), j = 0, 1 and the corresponding
lower cases as their estimated values. Further, let CVj be the covariance of µˆj(C)
and µˆj(E) and cvj be the corresponding estimated values, j = 0, 1. We define the
variances of ∆̂C and ∆̂E to be
(4.6) VC = V0(C) + V1(C)
and
(4.7) VE = V0(E) + V1(E),
with their estimated values being denoted vc and ve, respectively. Likewise, Cov(∆C,∆E)
is given by
(4.8) VC,E = CV0 + CV1,
with estimated values denoted cv0 and cv1, respectively.
The estimated values can be obtained from field data. For example, if S20(C) is
the sample variance of the n0 cost values in the sample for the baseline treatment,
S20(C)/n0 is an unbiased estimator of V0(C). We denote the estimated standard de-
viation (also called estimated standard error) of µ̂0(C) as ŜE(µ̂0(C)). The standard
errors and estimated covariances for the other quantities can be computed similarly.
There are two ways by which the estimation uncertainty can be incorporated
into the CEA analysis: hypothesis testing and confidence intervals. For example,
hypotheses of interest include the null hypothesis of: a) H0 : ∆(E) ≤ 0 against the
alternative H1 : ∆(E) > 0; b)H0 : ∆(C) ≥ 0 against the alternative H1 : ∆(C) < 0;
c)H0 : µICER ≤ λ against the alternative H1 : µICER > λ; or d) H0 : µNMB(λ) ≤ 0
against the alternative H1 : µNMB(λ) > 0. Hypotheses (a) and (b) are often tested
93
can sequentially – a) and then b) – since an advantage in terms of cost would be
attractive only if the treatment is more effective. In all cases, the problems are
formulated so that the null hypotheses favor the standard or baseline treatment, and
sufficient evidence is needed to reject it in favor of the new treatment. One can also
test two-sided hypotheses which test just whether the standard and new treatments
have the same effect, although this is not as meaningful in the CEA context.
In practice, hypothesis testing is less useful than estimating the difference in
the treatment effects and getting confidence intervals around the point estimates.
A confidence interval is more useful because it gives a set of plausible values for
the difference in treatment effects. The interval can also be used to test the null
hypothesis by determining if the hypothesized null value falls inside the confidence
interval or not. One (minor) disadvantage is that one has to specify a confidence
level a priori before the interval is computed, so different confidence levels may lead
to different conclusions about the hypotheses. On the other hand, one can compute
the p-values once for all for the hypothesis tests, and they provide an indication of
the evidence for or against the null hypotheses. We will illustrate the issues later in
the paper.
There are many papers in the CEA literature that have discussed the problem of
statistical uncertainty for mean-based comparisons. These papers discuss examples
and provide summary statistics on v0(E), v0(C), v1(E), v1(C), cv0, cv1, which are
needed for the analysis (see, for example, Willan (2001), Laska et al. (1997), van Hout
et al. (1994), and Chaudhary and Stearns (1996)). However, some of the methods
discussed in this paper, including resampling methods and stochastic dominance
comparisons, require the entire sample data, not just the summary statistics. Such
data are difficult to find in the literature. Thus, we will use artificial data, given in
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Appendix 4.6.1, to illustrate the methods and compare them.
4.3.1 Use of Large Sample Approximations for One-Dimensional CEA
Our goal here is to review the main techniques and also clarify some confusion
that seems to be present in a few CEA papers. The methods in this section depend
on a straightforward application of the central limit theorem, i.e., the distributions
of all the sample means are approximately normal when the sample sizes n0 and n1
are sufficiently large.
NMB
Since µ̂NMB(λ) is a linear combination of the sample means, it also has a normal
distribution in large samples. Specifically, [µ̂NMB(λ) − µNMB(λ)]/ŜE(µ̂NMB(λ)) is
distributed approximately as a standard normal random variable. The standard
error of µ̂NMB(λ) can be calculated as follows. Its variance is
V ar(µ̂NMB(λ)) = λ
2V ar(∆̂(E)) + V ar(∆̂(C))− 2λCov(∆̂(E), ∆̂(C))
= λ2[V1(E) + V0(E)] + [V1(C) + V0(C)]− 2λ[CV1 + CV0].
(4.9)
The last expression follows from the independence of the data for treatments 0 and
1. By plugging in estimates on the right-hand side and taking the square root, we
get the estimated standard error as
(4.10) ŜE(µ̂NMB(λ)) =
(
λ2[v1(E) + v0(E)] + [v1(C) + v0(C)]− 2λ[cv1 + cv0]
)1/2
.
One can now construct approximate confidence intervals as well as tests of hy-
potheses relating to µNMB(λ) (see Stinnett and Mullahy (1998)). For example, to test
if µB(λ) > 0 at level α, one can use the approximate (1− α)−level lower confidence
bound (LCB) for µB(λ): [µ̂B(λ) + zαŜE(µ̂B(λ)) where zα is the α−th quantile of
the standard normal distribution. If this LCB does not include zero, then one can
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decide that µB(λ) > 0 or that the new treatment is better than the current one in
terms of NMB (at this value of λ), even after accounting for statistical uncertainty.
Otherwise, one may decide to go with the current treatment. Similar tests can be
constructed for other hypotheses of interest.
The large-sample procedures will work well when the sample sizes for the field data
are sufficiently large. The general rule of thumb in statistics is that both sample sizes
should be at least 30. Clearly, the quality of the approximation will improve as the
sample sizes get bigger. As an aside, sometimes one sees the use of a t-statistic
(Laska et al., 1999) with the value of zα replaced by a quantile from a t-distribution
with some degrees of freedom when the sample sizes are small. The theory for t-
distribution is valid when the underlying distributions of both cost and effectiveness
random variables are (close to) normal, which is not likely to be the case here. We
note that there is no justification for doing this in the present context.
For our example, with λ = 50, 000, µˆNMB(λ) = 43, 810. A comparison based on
just the point estimate will suggest that the new treatment is cost-effective. Con-
struct a confidence interval, with ŜE(µˆNMB(λ)) = 30, 128, we get a 90% (large-
sample) lower confidence bound for µNMB(λ) as −15240; the corresponding 95%
two-sided confidence interval is (−15240, 102861). We see that, after incorporating
the statistical uncertainty, the new treatment is not cost-effective.
ICER
We can approximate [µˆICER − µICER]/ŜE(µICER) by a standard normal random
variable, and, as before, use this as the basis of large-sample inference. For example,
we can decide that µICER is greater than λ0 if the lower end-point of a one-sided
lower confidence bound for µICER at some specified level, say λU is greater than or
equal to λ0.
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This large-sample approach has been discussed in the CEA literature (see, for, ex-
ample, O’Brien et al. (1994); van Hout et al. (1994); Briggs and Fenn (1998)). There
is, however, some confusion. Some authors claim that the ratio will be approximately
a ratio of Cauchy random variables in large samples and that the distribution will
not have finite moments (Wakker and Klaasen, 1995; Siegel et al., 1996; Zethraeus
et al., 2003). The point about Cauchy random variables is wrong and appears to
arise from mistakenly equating the ratio[
∆̂(C)
∆̂(E)
]
−
[
∆(C)
∆(E)
]
with
[∆̂(C)−∆(C)]
[∆̂(E)−∆(E)] .
The latter does converge to a ratio of (correlated) normal random variables and
does not have any moments. But the former expression is the quantity of inter-
est. It can be approximated by a linear combination of random variables, each of
which converges to normal (as seen by equation (4.11)), so it has a limiting normal
distribution.
The issue of whether µˆICER has finite moments or not does not have any thing
to do with the large-sample approximation. It is indeed true that µˆICER =
∆̂(C)
∆̂(E)
may
not have a mean in finite samples. This is so when the distribution of ∆̂(E) gives
positive mass to any region that includes zero, and it can also be true in other cases.
However, as the sample size gets larger, the variance of the estimator decreases, so
both the numerator and the denominator will get closer and closer to their true
values. So, in large samples, the existence of moments is not an issue.
The simplest approach for large-sample inference is to use a direct approximation
of the distribution of µˆICER using a first-order Taylor series expansion. This leads to
(4.11) µˆICER − µICER ≈ 1
∆2(E)
(
∆(E)[∆̂(C)−∆(C)]−∆(C)[∆̂(E)−∆(E)]
)
.
Since ∆ˆ(E) and ∆ˆ(C) have large-sample normal distributions, the large-sample nor-
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mality of µˆICER follows. The above linearization also yields the following approxi-
mation for the variance:
V ar(µˆICER) ≈ 1
∆4(E)
(
∆2(E) V ar(∆̂(C)) + ∆2(C)V ar(∆̂(E))
−2∆(E)Cov(∆̂(E), ∆̂(C))
)
=
1
∆4(E)
(
∆2(E) [V0(C) + V1(C)] + ∆
2(C) [V0(E) + V1(E)]
−2∆(E) [CV1 + CV0]) .
(4.12)
The estimated standard error of µˆICER is obtained by substituting the estimates and
taking the square root.
For our illustrative example, µˆICER = 25407 which is less than the λ = 50000.
ŜE(µˆICER) = 300387, indicating huge variability in the estimate. The large-sample
two-sided 95% confidence interval is (−18249, 69064). It contains zero, suggesting
that the differences in cost or effectiveness are not very large (most likely the differ-
ence in effectiveness). The negative value is difficult to interpret on its own, since
this could be due to increased effectiveness and decreased cost or to decreased effec-
tiveness and increased cost, or to estimation uncertainty in either variable. We will
address this issue in Section 4.3.3
It is well known in the statistical literature that ratio estimators, such as µˆICER,
can be unstable and that very large sample sizes are needed before the normal ap-
proximation will be adequate. For this reason, alternative methods of constructing
confidence intervals and hypothesis tests have been proposed. The most common one
is Fieller’s method, which has been discussed also in the CEA literature (Chaudhary
and Stearns, 1996; Polsky et al., 1997; Briggs and Fenn, 1998). Perhaps the simplest
way to motivate this approach is as follows. It is well known in statistics and has
also been rediscovered in the CEA literature (see Zethraeus et al. (2000)).
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Recall that µICER = λ if and only if µNMB(λ) = 0. Suppose we used the large-
sample distribution of µ̂NMB(λ) to determine the set of values of λ for which we will
we accept the null hypothesis that µNMB(λ) = 0. Then, from the 1-1 relationship
between µICER = λ and µNMB(λ) = 0, this set of values of λ will yield a confidence
region for µICER. Because the distribution of µ̂NMB(λ) is more stable (it is just a linear
combination of the random variables) than that of µ̂ICER, the resulting confidence
region will also be more stable and will have better properties. The issue now is how
to construct such a confidence region, whether the region will actually be an interval
or disconnected, if it is an interval, whether it is finite. (Fieller, 1954) showed that,
under certain conditions, the interval exists and is given by
1
1− g
[
µˆICER − gvC,E
v E
∓ zα/2
∆̂E
(
vC − 2µˆICER vC,E + µˆ2ICERvE − g
(
vC −
v2C,E
vE
))1/2](4.13)
where g = z2α/2vC/(∆̂
2(E)). For our illustrative data, Fieller’s method gives the
following 95% confidence interval: (−23883, 58059). This is shifted to the left and
shorter than the interval from the direct large-sample normal approximation, but
still includes the value of zero.
The methods discussed thus far can also be used to test various hypotheses related
to µICER or µNMB. See, for example, Gardiner et al. (2000).
4.3.2 Resampling Methods for One-Dimensional CEA
We discuss two alternatives to large-sample methods based on resampling the
data. The first is the randomization test (also called permutation test) and the
second is bootstrap. Although both involve resampling the data, their goals are
different. Randomization attempts to get the null distribution of a test statistic; here
the sampling is done without replacement. Bootstrap, on the other hand, attempts
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to get the actual distribution of an estimator or test statistic; further sampling is
done with replacement.
Randomization tests have a long history in statistics and are based on a very
simple idea. If the new treatment and the current one are not different, then the
two sets of data should have the same distribution. Consider a generic two-sample
problem where N = n0 + n1 subjects were randomly assigned to two treatments.
Let {Y0,1, ..., Y0,n0} be the data from one treatment and {Y1,1, ..., Y1,n1} be the data
from a second treatment. Let Z be an appropriate test statistic, such as (Y¯1 −
Y¯1)/ŜE(Y¯1 − Y¯0), the standardized difference of the sample means. Let {V1, ..., VN}
be the combined data. If there is no difference among the two treatments, we can
randomly partition the V data into two groups of size n0 and n1 and compute a new
value of the test statistics, say Z∗, for the new data set. The Z∗ should have the
same distribution as Z under the null hypothesis. If we do this for all
(
N
n1
)
possible
partitions of {V1, ..., VN} into two samples of size n1 and n0, we get
(
N
n1
)
possible
values, and hence the distribution of Z. Now, if the observed value of Z for our
original data set falls in the tails of this distribution, we can interpret it as evidence
that the null hypothesis of no treatment effect is not appropriate. See Lehmann
et al. (2005) and references therein for more details. If the sample size is large, the
permutation distribution can be approximated by a normal distribution (and this
will lead to the same results as in the last section).
In the case of CEA, randomization tests can be used on the any of the statistics:
differences in sample means of costs and effectiveness, NMB, or ICER. We illustrate
it on NMB and test whether µNMB > 0 or equivalently whether µ1(MB) > µ0(MB).
Define the Y0−random variable to be MB0 from the illustrative example, and the
Y1−random variable to be MB1. In this case, n0 = n1 = 32 and N = n0 + n1 = 64.
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Since the value of all possible partitions,
(
N
n1
)
, is very large, we randomly sampled
10, 000 permutations, and calculate 10, 000 values of Z∗ statistics. The test value for
the actual sample is 1.59, which has a p-value of 0.07 based on the bootstrap sample.
Thus, the effect is marginal.
The bootstrap represents a different approach to the problem. There are many
refinements of the original bootstrap approach suggested by Efron (1979). Some of
them have also found their way into the CEA literature. See, for example, Briggs
and Fenn (1998) and O’Brien et al. (1994), with examples in Chaudhary and Stearns
(1996) and Hunink et al. (1998). The basic idea is to resample data, separately and
with replacement, from each of the two samples. Repeatedly sampling and computing
the value of the statistic gives us a distribution which can be used to approximate
the true distribution. Again, the idea can be used to approximate the distribution
of any of the statistics we have discussed thus far. There are several variations of
the bootstrap for testing hypotheses and constructing confidence intervals (see Efron
and Tibshirani (1993) and Briggs and Fenn (1998) in the CEA literature). Perhaps
the most common is the percentile method which used the 100(α/2)-percentile and
100(1 − α/2)-percentile of the bootstrap distribution as confidence limits for the
difference in treatment effect. Other common approaches include the bootstrapped
t-statistic (see Jiang and Zhou (2004) in the health economics literature) and the
bias-corrected, accelerated bootstrap (see Efron and Tibshirani (1993)).
We illustrate bootstrapping with the simple percentile method and compare it
with the results from the large-sample approximations for µICER. Using a bootstrap
procedure to create 10, 000 samples in the illustrative example of µˆ∗ICER and the
percentile method results in a 95% confidence interval for µˆICER of (−14702, 61726).
This interval is similar to, but narrower than, those based on the Fieller and large-
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sample normal approximations.
4.3.3 Two-dimensional CEA Based on Mean Metrics
Use of Large Sample Approximations
We can incorporate estimation uncertainty in the two-dimensional setting along
the same lines as before. For example, we can use the large-sample approximations
to get confidence intervals for ∆̂(C) and ∆̂(E) separately. Recall the definitions of
the variance of ∆̂(C) given in Equation (4.6) and for ∆̂(E) given in Equation (4.7).
We know that ∆̂(E) and ∆̂(C) are approximately (and jointly) bivariate normal
with mean ∆(E) and ∆(C) and variance covariance matrix Σ which can be estimated
by
Σˆ =
 vE vC,E
vC,E vC
 .
A conservative, rectangular joint confidence region that does not depend on the
correlation between the two random variables can be obtained using the Bonferroni
bound (see O’Brien et al. (1994) in the context of CEA). Let the one-dimensional
confidence intervals with levels (1 − α1) for ∆̂C and (1 − α2) for ∆̂E be given by
[∆̂C ± zα1/ŜE(∆C)] and [∆̂E ± zα2/ŜE(∆E)]. Taking the intersection of these two
regions in the two-dimensional plane yields a rectangular confidence region. From the
Bonferroni bounds, the confidence level of this region is greater than (1−α1−α2). It
is common to take α1 = α2 = α/2 to get an overall (1−α)−level region. Figure (4.3)
shows the confidence box region for the illustrative example.
It is well known that this rectangular confidence region is not efficient in such
cases because: a) the Bonferroni bound used to combine the two intervals is conser-
vative; and b) an ellipsoidal confidence region that takes into account the correlation
structure is more efficient (smaller is area for a given level). The ellipsoidal region is
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Figure 4.3: Cost-effectiveness plane with 95% confidence regions: Rectangular region based on
Bonferroni bound and elliptical region.
constructed as follows (see van Hout et al. (1994) for a discussion of this in the CEA
literature). Define the vector
X = [∆̂(E)−∆(E), ∆̂(C)−∆(C)]T .
Recall that XT Σˆ−1X is approximately distributed as χ2(2), a chi-squared random
variable with two degrees of freedom. Let Kα be the (1 − α)−th upper quantile of
the χ2(2) distribution. Then, the set of {(∆(E), ∆(C) : XT Σˆ−1X ≤ Kα} yields an
approximate (1−α) joint confidence region for (∆(E), ∆(C) in the two-dimensional
plane. This region is an ellipse as shown in Figure( 4.3) for the illustrative example.
Figure (4.3) illustrates the elliptical and rectangular confidence regions for our ex-
ample CEA; one can discern that the ellipse covers a smaller area than the rectangle.
We can also see that the point (0, 0) is outside the ellipse as well as the rectangular
region, so the corresponding null hypothesis will be rejected at this confidence level
using either method. Both confidence regions include the point ∆(C) = 0, suggesting
that there is no statistically significant difference in cost between the two treatments.
103
Figure 4.4: Cost-effectiveness plane with 95% rectangular confidence regions: bootstrap rectangle
(dashed) with large-sample normal approximation (solid) shown for comparison
.
Resampling Methods
Resampling methods have also been used to get confidence regions in two dimen-
sions. In the CEA context, Briggs and Fenn (1998) discussed the rectangular region
using bootstrapping and Bonferroni bounds. We use our data example again to il-
lustrate this approach. The two-dimensional rectangular region, based on 10, 000
replications, using the percentile method is shown in Figure (4.4). The dotted line
is the region using the bootstrap, and the large-sample normal approximation (solid
line) is also shown for comparison. The region using the bootstrap is somewhat
larger and asymmetric (about the estimates), suggesting that the large-sample ap-
proximation is not as good, especially for the cost dimension.
One can also use the bootstrap the distribution of XT Σˆ−1X to get the critical
value Kα instead of using the χ
2 approximation. The details are very similar and
are omitted.
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4.3.4 Use of Rank Statistics
The methods so far deal with mean-based metrics and the statistical uncertainty
that arises from estimating them. As noted earlier, the differences in means coincide
with differences in other location parameters in some special cases. In this section, we
propose a method for assessing the median of the difference in treatment. It is based
on ranks of the data rather than the original numerical values. When the median
of the differences coincides with the mean, this procedure can be used as a robust
alternative to the sample mean-based statistical procedures. The method can be
more efficient than sample mean-based methods when the underlying distributions
have heavier tails than normal, such as the logistic and double exponential.
There is a huge literature on rank-based methods (see, for example, Lehmann
and D’Abrera (1975)). We focus here on just the Wilcoxon test (sometimes called
the Mann-Whitney test), which has been widely used. There has been discussion of
Wilcoxon rank-sum test in the CEA literature. There is a discussion of sample sizes
needed to achieve statistical power for a Wilcoxon test for ICER in Laska et al. (1999).
Mark et al. (1995) use the Wilcoxon rank-sum test to identify differences in resource
consumption between treated and untreated groups, and uses those differences to
estimate cost differences; Mehta et al. (1997) also used the Wilcoxon rank-sum test
to identify significant differences in cost categories, and actually forms CE-ratios
using medians instead of means.
The Wilcoxon test procedure works as follows. Let {Y1,i, i = 1, . . . , n1} be the
data for the n1 patients assigned to Treatment 1 and {Y0,j, j = 1, . . . , n0} be the data
for the n0 patients assigned to Treatment 0. Let N = n1 +n0 and {Zk, k = 1, . . . , N}
be the combined Y0 and Y1 data. Rank the Zk’s and let S1 < ... < Sn1 be the ranks of
the Y1’s among the Zk’s. (We assume there are no ties. The case with ties can be also
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handled and we refer readers to Lehmann and D’Abrera (1975)). Let W =
∑n1
i=1 Si.
If there was no difference between the new and old treatments (null hypothesis), Ws
is symmetric with expected value n1(N + 1)/2 and variance n0n1(N + 1)/12. If the
new treatment is better, then Ws will tend to be larger. We need to know the null
distribution of Ws to develop formal tests.
We can use a randomization framework (same as the one used earlier) to get the
null distribution as follows. If there is no difference among the two treatments, all
the Zk values come from a homogeneous group. So we can randomly take a sample
of n1 values from the Zk’s, assign them to treatment 1 (call them Y1’s) and assign the
remainder to treatment 0 (call them Y0’s). Doing this will result in a value of W
∗
s .
There are
(
N
n1
)
possible ways we can do this. All of these possible values provide the
null distribution of Ws. To test the null hypothesis at level α, take the (1 − α)−th
quantile of the null distribution and reject the null hypothesis if the observed value of
the data is greater than this quantile. (see Lehmann et al. (2005) for more details).
If n0 and n1 are both moderate (say bigger than 30), then the distribution of Ws
can be approximated by a normal distribution with mean n1(N + 1)/2 and variance
n0n1(N + 1)/12. This can be used to get large-sample test procedures. It turns
out that the Wilcoxon test is consistent for testing the general hypothesis F1 = F0
against F1 ≤ F0 (treatment 1 is more effective than treatment 0).
We illustrate the results on the difference in monetary benefits using our data,
so the two distributions of interest are MB0 and MB1. The value of the Wilcoxon
statistics is W = 1370. Using 10, 000 random samples from the full set of possible
permutations, the randomization analysis yields a lower 5% critical values as 913,
indicating a difference in the two distributions. The use of the large-sample normal
approximation, instead of the permutation distribution, gives a critical value of 917,
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very close to the randomization result.
A more interesting problem is getting confidence interval for the difference in the
treatment effects. Consider the n0n1 differences Y1,i − Y0,j. Let D(1) < ... < D(n0n1)
be the ordered values of these differences. Then, the estimate of the median of the
differences Y1,i − Y0,j is estimated (naturally) by the median of the corresponding
sample values, i.e., median of the D(k)’s. This is referred to as the Hodges-Lehmann
estimator in the statistical literature (Lehmann and D’Abrera, 1975). Note that
when the medians coincide with the mean, this estimator provides an alternative
way to estimate the differences in the means. It tends to be robust to outliers in
the data. It can also be more efficient (in a statistical sense) when the underlying
distribution has heavier tails than a normal distribution, such as logistic or double
exponential. Note also that the ranks are invariant to monotone transformations of
the data, provided the same transformation is applied to data from both treatments.
Exact confidence intervals for the Hodges-Lehmann estimator can be based on the
Wilcoxon rank-sum test. The critical values Cα/2 form a two-sided confidence interval
when n0 and n1 are small have been tabulated in the literature. With sufficiently
large samples, one can use large-sample approximation (Lehmann and D’Abrera,
1975) given by
(4.14) Cα/2 ≈ n0n1/2− Zα/2 (n0n1(N + 1)/12)1/2
The Cα/2 should be taken to be the nearest integer. The confidence interval for the
median difference is then given by (D(Cα/2), D(n1n1+1−Cα/2)).
For our data, the Hodges-Lehmann estimator is 54201, indicating an overall cost-
effective treatment effect. The confidence interval using the large-sample approxi-
mation for the distribution is (25250, 81985). It is noteworthy that this confidence
interval is entirely positive, in contrast to the case for the means. This suggests that
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the distributions are not symmetric, so the two quantities are estimating different
treatment effects.
The performance of various rank methods have been compared in the statisti-
cal literature (Lehmann and D’Abrera, 1975). In particular, it is known that the
Wilcoxon procedure does well when the underlying distributions are logistic. Alter-
natives that work well with other distributions, such as the normal scores, have also
been proposed.
4.3.5 Paired Data Analysis
Most of the CEA literature deals with the case where the field data for the stan-
dard and new treatment are independent. This is the most common situation –
there is likely to be considerable field data on the standard and small studies are
then conducted to collect data on the new treatment. It is, however, possible that
the two treatments are compared in the same study and that the two treatments are
assigned to subjects in such a way that the responses are paired or correlated. In this
case, one would just take the difference in the responses (cost and effectiveness) and
analyze the differences as one-sample iid data. Both large-sample approximations
and resampling methods can be used with the one-sample data.
4.3.6 Censored Data
Incorporating uncertainty when the data are censored does not appear to have
been discussed in the CEA literature, so we provide an overview here. Perhaps the
most common type of censoring in clinical trials is fixed time censoring: the study is
stopped at some fixed (prespecified) time and some subjects are alive at the end of
the study. There can be other, more complex forms of censoring, including multiple
right censoring where different subjects are right censored at different times.
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Consider first the case of fixed time censoring. Specifically, suppose data from
both samples are right censored at the same time t0. Then, we cannot estimate
the means of the underlying distributions from the data since we do not have any
information on when the subjects that were alive at time t0 would fail. So, one
cannot use the mean-based metrics. However, we can base the comparisons on the
conditional means – E[Y |Y ≤ t0] – since this quantity can be estimated from the
data. If the data from the two samples are right censored at different times, we have
to take the conditional distribution at the minimum of the two censoring times. One
could estimate median-based metrics from the sample data if the number of censored
observations is smaller than 1/2 for both samples.
The problem is more complex if there is multiple right censoring. However, sev-
eral of the rank-based methods for comparing two populations have been extended
to censored data in the statistical literature. These include generalizations of the
Wilcoxon test and the log-rank test (see Lawless (2003)), with the latter being the
most common.
4.4 Beyond Mean-Based CEA Analysis
We have focused thus far on CEA based on single-number metrics: means, median,
and expected utilities. The remainder of the paper focuses on CEA based on the full
distribution of cost and effectiveness outcomes.
To motivate this analysis, consider Figure (4.5) which shows a hypothetical ex-
ample, the cumulative distribution functions of (say) effectiveness outcomes for a
standard and a new treatment, measured in life-years. In this case, the treatment
improves the mean length of life from about 4.4 years to 5 years, so mean-centric
decision-making would recommend adopting the treatment. However, the median
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Figure 4.5: Hypothetical Effectiveness Distribution.
length of life under treatment actually decreases from 4.2 years to 3.5 years. We can
see from the figure that this occurs due to a long upper tail under the new treatment,
which raises the mean for some of the treated population, but has no benefit for most
of the population. In fact, the treatment lowers effectiveness for about 60% of the
population. The nature of the treatment effects are complex and cannot be charac-
terized by just the differences in means, and different metrics can lead to different
decisions. While a health analyst or decision-maker may still prefer to implement the
treatment, an analysis of the two distributions will provide much more information
about the trade-offs being made and the risks.
4.4.1 Utility Functions
Utility functions provide a natural way to map the cost and effectiveness outcomes
into a decision-theoretic framework in the sense of von Neumann and Morgenstern
(Von Neumann and Morgenstern, 1947). There is a huge literature on this topic,
and we touch on it very briefly.
Using just the means is equivalent to assuming a utility function that is linear
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in the outcomes – in other words, being risk neutral (Keeney and Raiffa, 1976).
This is inadequate in many situations. For example, a person is not likely to be
indifferent between a placebo that has no effect on his/her life expectancy versus a
new treatment that offers a 50% chance of doubling life expectancy but carries a
50% risk of instant death, but these two options offer the same expected utility to a
risk-neutral decision maker. In fact, it is known that patients will exhibit different
behaviors – risk-seeking, risk-averse, and risk-neutral, depending on the situation at
hand (Pliskin et al., 1980). It is also generally recognized that policymakers tend to
be risk-averse – concerned about new interventions being extremely harmful with a
small probability, or concerned about budgetary problems (Koerkamp et al., 2007).
In the rest of this section, we consider comparisons based on expected utilities. If
the utility functions are fully specified, then the problem of incorporating statistical
uncertainty of estimated parameters using utility functions is the same as with the
estimated mean. Consider a particular outcome, say, cost. We can treat the utility
outcomes as the new random variables of interest, estimate their means using the
sample data and incorporate statistical uncertainty using one of the methods that
have already been described.
But the utility functions are rarely known completely. Here we restrict attention
to functions of the form U(x) = (x+ b)c, with 0 < c < 1, a class of risk-averse utility
functions (Keeney and Raiffa, 1976), and examine the sensitivity of the decisions
to the values of b and c. Suppose that the distributions for the MB outcome are,
again, the same ones in Figure (4.2): F0 = LN(10, 0.5) and F1 = LN(9, 2). Suppose
b = 100 and c = 0.3, and so u(x) = (x + 100)0.3. For this case, treatment 1
has an expected utility of 17.9 compared to 20.3 for the standard, so the standard is
preferred. (Recall that treatment 1 had a higher expectation than the standard, even
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though the standard was better than the new treatment up to the 75th percentile.)
However, the parameters b and c are usually unknown, so let us examine how the
comparisons change as the values of b and c change. First, consider a sensitivity
analysis. The left panel of Figure (4.6) shows how the difference in expected utilities
change as b varies with c fixed (at several different values).
Figure 4.6: An examination of the differences in utilities for the utility function: u(x) = (x + b)c.
Left: b varies in the x-axis with c fixed at several values. Right: c varies in the x-axis with b fixed
at several values.
Note that the difference in expected utility is negative over the entire range of b
when c = 0.1 or c = 0.2, indicating that the standard treatment 0 is better than the
new treatment 1. When c = 0.3, the difference in negative for b ∈ (0, 16000) and
positive thereafter. As the value of c gets larger, treatment 1 has higher expected
utility for even relatively small values of b. The right panel shows a different view,
with c changing but the value of b fixed at different levels. For smaller values of b,
treatment 0 dominates treatment 1 for all values of c up to about 0.5. As b gets
larger, the situation reverses, but the behavior in the right panel is more stable than
that in the left panel.
We can represent this information simultaneously in the surface plot in Fig-
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Figure 4.7: Three-dimensional surface plot of the difference in expected utilities as both b and c
ure (4.7). Here, the x- and y-axes show different values of b and c while the z−axis
shows the difference in expected utilities. Figure (4.8) provides yet another view of
the comparison of the two treatments in terms of expected utilities. The plot divides
the two-dimensional b and c space into two regions: one where the new treatment 1
is preferred and the other where the standard treatment 0 is better. Such analyses
are useful in examining the sensitivity of the parameters in a class of utility functions
and provides the decision-maker with additional information.
Many other assumptions about utility are implicit in standard cost-effectiveness
analysis, including the idea of a constant willingness-to-pay that relates cost and
QALYs; the particular values chosen for quality weights; and social welfare consider-
ations. Modeling full multiattribute utility functions and also assessing the requisite
preference data from decision makers are important tasks which are separate from
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Figure 4.8: Preference Regions Relative to Utility Function Parameters.
the estimation of treatment effects. However, it is useful to consider some of the
complexities of utility modeling in order to generate the appropriate results from
statistical estimation (most importantly full distributions instead of mean values
only).
4.4.2 Stochastic Dominance
When there is consensus about the utility functions or if the decision is robust
over a range of functions, it is indeed reasonable to base decisions on expected utility
criteria. More often than not, however, this is not the case. Utility functions of
various individuals and groups (patients, decision makers) can differ greatly within
and across groups.
The finance literature uses mean-variance ordering (Markowitz, 1952) to com-
pare distributions. The mean-variance rule is part of portfolio theory which seeks to
maximize a portfolio return for a given amount of risk, or minimize risk for a given
amount of return. The rule is used to construct an efficient portfolio of investment
opportunities for a risk-averse investor; an investment opportunity is considered in-
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efficient (and discarded) if it has a lower mean and higher variance than another
(Bawa, 1975). We can also consider the use of a similar rule in CEA to determine
an efficient set of interventions. An efficient group of interventions would have rela-
tively high expected NMB and relatively low variance. However, the mean-variance
rule depends on the decision-maker having a quadratic utility function (Tobin, 1958;
Borch, 1969; Feldstein, 1969).
From a health policy perspective, if a treatment increases the variance of out-
comes, it is then important to try and identify the subset of the population for which
the treatment helps and the subset for which it is harmful. Of course, if a policy-
maker is truly indifferent to how medical effects are distributed in the population, the
mean-maximizing policy may be fine. In practice, however, implementing policies
that overtly help one group of patients while ignoring others would be problematic
and possibly unethical.
It is important to recognize at least two different sources of variability – one
due to identifiable differences in patient characteristics and a second due to intrinsic
variation in a homogeneous group of people. In the case of variability due to patient
medical conditions, targeted treatments may be desirable: for instance, treatments
that are most effective at preventing heart attacks in high-risk populations, such as
those with high blood pressure. Treatments that are more effective or cost-effective
along racial or gender lines, however, may be more controversial. Of course, this
separation by patient characteristics can often be murky. Further, even if there are
obvious patient characteristics that cause the difference, the medical intervention
may not be tailored by patient groups for various reasons. Nevertheless, during the
analysis stage, it is important to separate patients into homogeneous populations
and analyze the populations separately. The results can then be combined at the
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decision-making stage.
All of this discussion is intended to make a case for examining the entire distribu-
tion of outcomes for the standard and new treatments and determine areas where one
is better than the other. There are graphical techniques as well as formal methods
for comparing distributions. We focus on formal methods based on the notions of
first- and second-order stochastic dominance (SD) here. The SD concepts have been
discussed extensively in the finance and economics literature.
SD is a useful, and thus far largely overlooked, tool in CEA. There is brief men-
tion applied to Net Health Benefits (equivalent to NMB) in Stinnett and Mullahy
(1998), but with no consideration of the separate outputs of costs and effectiveness
or uncertainty. It is also mentioned in Laska et al. (1999) but the focus of the paper
is on the estimation of sample size to achieve power in statistical tests in CEA, and
there is no analysis of the broader implications of SD on decision-making. There
are very few papers in the more general literature about stochastic dominance for
medical decisions of which we are aware. The first, Leshno and Levy (2004) deal with
the advantages of SD for deciding optimality among a finite set of options. It did
not deal with the question of estimation uncertainty. Finally, Sendi et al. (2003) use
SD to evaluate a portfolio of health interventions. Their decision-making framework
and decision rules are a bit different from those in CEA. Sendi et al. (2003) assume a
fixed budget and that health programs are not divisible; in CEA, the existence of any
hard upper-bound on budget is usually ignored in favor of discussion about whether
an intervention is a good investment, and interventions are implicitly considered to
be divisible, so that they may be implemented in whole or in part from most to least
cost-effective until the budget is exhausted. As a result of the budget constraint,
Sendi et al. (2003) establish that a portfolio is better than a comparison portfolio
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Figure 4.9: Demonstration of Stochastically Smaller Distributions. Left: F1  F0. Right: No FSD.
through dominance in effectiveness while maintaining a pre-specified probability of
remaining within the budget. The appropriate decision when a first-order stochastic
dominant portfolio does not exist is not discussed.
In the remainder of this section, we review the use of SD methods for CEA (assum-
ing that the distributions are known) and then propose methods for incorporating
estimation uncertainty. The latter topic has not been studied in the CEA literature.
First-Order Stochastic Dominance: FSD
Consider a general set up with two CDFs: F1(x) and F0(x) and define the differ-
ence D(x) = F1(x)−F0(x). We say that F1 is stochastically larger (in the first-order)
than F0 (written as F1 1 F0) if F1(x) ≤ F0(x) or, equivalently, D(x) ≤ 0 for all
x with strict inequality for some x. A similar statement can be made about F1
dominating F0 in first order. In other words, the CDF of the stochastically smaller
distribution will always be larger than that of the dominating distribution. Recall
that F1(x) being smaller than F0(x) means that the outcomes tend to be larger un-
der F1 than under F0. Perhaps a more intuitive way to describe this is in terms
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survival functions F¯j(x) = 1 − Fj(x), j = 0, 1. So F1 FSD F0 (denoted F1 1 F0)
if F¯1(x) ≥ F¯0(x) for all x with strict inequality for some x. Clearly, FSD implies
E(X1) > E(X0).
The left panel of Figure (4.9) demonstrates a situation where F1 1 F0, and the
right panel demonstrates a situation where neither distribution dominates the other.
In Figure (4.9), regions under the curves in each panel are highlighted; these regions
will be discussed in the context of second-order stochastic dominance.
FSD is also known to have a characterization in terms of utility functions. If
F1 1 F0, then E1(U(X)) > E0(U(X)) for all increasing utility functions. (For
comparing costs where smaller is better, we can take negative cost values). For this
reason, an FSD comparison is the first one to make for a pair of treatments. When
such dominance does not exist, then we can compare them in terms of more restricted
dominance criteria or examine partial dominance (to be discussed later).
Figure 4.10: Cost and Effectiveness Cumulative Distribution Functions of Treatments with FSD in
Monetary Benefit.
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Figure 4.11: Monetary Benefits Cumulative Distribution Functions of Treatments with FSD.
A two-dimensional analysis for FSD involves comparing separately the distribu-
tions of costs and effectiveness for the two treatments. A medical decision that is
FSD in both cost and effectiveness is unequivocally better and there is no tradeoff
between QALYs and cost. However, most new medical treatments typically increase
effectiveness and cost. The basis of CEA is that treatments with increased cost are
worthwhile as long as there is adequate increases in QALYs.
To understand the trade-off, we can convert effectiveness into monetary units as
in the case of NMB. Recall monetary benefit (MB) of treatment j, defined earlier
as MBj = λEj − Cj, j = 0, 1. Letting F1 and F0 be the distributions of MB1 and
MB0 respectively, we can now assess SD in terms of MB. MB can be dominant even
if neither costs nor QALYs of that treatment are dominant. Figures (4.10) and
(4.11)show an example. The CDFs of cost and QALYs cross, so there is clearly no
FSD in these. However, Figure (4.11) shows that there is FSD of treatment 1 over
treatment 0 in terms of MB.
If there are multiple treatments, pairs of treatments can be evaluated against
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each other, or even portfolios of treatments. In this case, rules based on stochastic
dominance are used to discard non-optimal choices. In general, the efficient set of
medical choices are those that are not dominated by any other option. If the number
of options is large, it may be computationally demanding to do pairwise compar-
isons for stochastic dominance between all distributions. There exist algorithms for
reducing the number of pairwise comparisons and finding the efficient set of options,
also referred to as the admissible set (Porter et al., 1973; Bawa, 1975; Bawa et al.,
1979). Regardless of the method used to determine the efficient set of options, the
result may be a large efficient set of options, as the framework may be unable to rank
two risk options (Levy and Hanoch, 1970). We will primarily focus on the pairwise
comparison of two interventions in this paper, but simple extensions are available to
the construction of an efficient set of interventions.
Second-Order Stochastic Dominance
FSD is a fairly stringent condition, and it may not hold in many situations. So
researchers have developed weaker SD criteria called second- and third- order SD
that also have interpretations in terms of utility functions. We will focus just on
second order SD here.
Define Gi(x) =
∫ x
−∞ Fi(y)dy for i = 0, 1. That is, Gi(x) is the area under the
curve of Fi up to the point x. Define
(4.15) L(x) = G1(x)−G0(x) =
∫ x
−∞
D(y)dy =
∫ x
−∞
(F1(y)− F0(y))dy.
We say that F1 dominates F0 in the second order sense (F1 2 F0) if L(x) ≤ 0
for all x with strict inequality for some x. Figure (4.12) show the areas under the
CDF curves for F0(x) and F1(x) for two different scenarios. The value of the line
representing F0 in the left panel in Figure (4.12) at NMB= 30000 corresponds to the
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Figure 4.12: Area Under the Curves. Left and Right: F1 2 F0
area shaded under the curve of F0 in the left panel in Figure (4.9). In the left panel,
F1 1 F0, so F1 2 F0 by definition. In the right panel F1 2 F0, but Figure (4.9)
shows that there is no FSD.
It is known that if F1 2 F0, then E1(U(X)) > E0(U(X)) for decision makers
who are risk-averse (which is to say they have increasing and concave utility func-
tions). More specifically, for any utility function that is differentiable, increasing
and concave, E1(U(X)) > E0(U(X)). Thus, the SSD criterion orders distributions
within a more restricted class of utility functions than FSD. It can be shown that
L(∞) = µ1 − µ0, so SSD also implies µ1 > µ0.
We can again apply the SSD comparisons separately to the distributions of cost
and effectiveness or do a reduced comparison in terms of MB1 and MB0 as discussed
in the case of FSD. A reduced comparison would suffice for a risk-averse decision
maker who cares only about cost-effectiveness, whereas the separate comparisons
are more informative for decision-makers with specific effectiveness goals or cost
constraints.
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Almost Stochastic Dominance
It is quite likely that there is no strict dominance of the one treatment over
another, in terms of cost and effectiveness, or even the combined measure of MB.
In this case, there may be ethical issues concerned with the choice of treatment due
to its differential effect in different regions and whether it helps some segment of
the population and harms others. The question of costs and ethics in healthcare is
more complicated due to the many different methods of insurance and payment in
the United States healthcare system.
Suppose there is no FSD and let
(4.16) S1(F1, F0) = {x ∈ (0,∞) : F0(x) < F1(x)},
the region where F0(x) < F1(x). Recall that no FSD implies that the CDFs cross at
one or more points or that D(x) = 0 for some values of x ∈ (∞,∞). If the crossings
occur at only one point, say x0, then the region will be an interval of the form
(−∞, x0) or (x0,∞); otherwise it will be a union of multiple intervals. Note that the
probability of the area S1 is the same under F0 and F1 since they cross at the end-
points of the intervals that form the regions S1. For example, consider Figure (4.13).
D(x) = 0 at x = a1, x = a2, and x = a3, so P (a1 < X0 < a2) = F0(a2) − F0(a1),
equals P (a1 < X1 < a2) = F1(a2)− F1(a1).
In any case, S1 provides information about the segments of the population where
F0 is better than F1. Suppose F1 1 F0 for the most part, and the probability of
the regions where F0(x) < F1(x) is small. Then, one possible notion of almost or
−FSD is that the total probability of the regions where FSD is violated is smaller
than some threshold .
One problem with this notion is the difference F0(x) − F1(x) can be big in this
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Figure 4.13: Conditional Dominance.
region even though the probability of the region is small. To get around this problem,
Leshno and Levy (2002) use an alternative notion of almost stochastic dominance
that depends on the area under the curve. Denote the integrated absolute difference
between F1 and F0 as ||F1 − F0|| =
∫∞
−∞ |F1(x) − F0(x)|dx. This quantity exists if
both F1 and F0 have finite absolute first moments. It can be viewed as one measure
of the difference between the two distributions. Then, Leshno and Levy (2002) say
that F1 almost dominates F0 in FSD (AFSD) if
(4.17)
∫
S1
[F1(x)− F0(x)]dx ≤ ε||F1 − F0||,
with ε ∈ (0, 0.5). In other words, the difference in the area under the curve where
F0(x) < F1(x) is relatively small compared to the total area. Leshno and Levy (2002)
show that, if F1 dominates F0 in terms of AFSD, then F1 is preferred over F0 for all
utility functions that are increasing but have a bounded derivative, where the bound
depends on ε. As  → 0, this class approaches the class of all increasing utility
functions.
Leshno and Levy (2002) also define ASSD similarly. Let S2(F1, F0) = {x ∈
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Table 4.1: Almost Stochastic Dominance Example Probability Distribution.
Rate of Return: z 5% 7% 9% 12%
P (X = z) 0.1 0.0 0.0 0.9
P (Y = z) 0.0 0.4 0.6 0.0
S1(F1, F0) :
∫ x
−∞ F0(y)dy <
∫ x
−∞ F1(y)dy}, the region where the SSD dominance of
F1 over F0 fails. Then, Leshno and Levy (2002) define almost SSD as follows. F1
almost dominates F0 in SSD (ASSD) if
(4.18)
∫
S2
[F1(x)− F0(x)]dx ≤ ε||F1 − F0||
and µ1 ≥ µ0. As before, ε ∈ (0, 0.5). Leshno and Levy (2002) show that, if F1
dominates F0 in terms of ASSD, then F1 is preferred over F0 for all utility functions
that are increasing and concave with bounded second derivative, where the bound
depends on ε. Again, as  → 0, this class approaches the class of all increasing and
concave utility functions.
As shown in Leshno and Levy (2002), there are many situations where one would
prefer F1 over F2 in terms of AFSD or ASSD (and for most reasonable utility func-
tions in their respective classes) but there is no (absolute) FSD or SSD. One example
in Leshno and Levy (2002) is a comparison of the utility of stocks (X) and bonds
(Y ). The distribution of the one-year rate of return is given in Table 4.1. Consider
X(n) to be the distribution of X after n years, and Y (n) to be the distribution of Y
after n years. The CDF of X(n) starts to the left of the CDF of Y (n), so FSD of X(n)
over Y (n) does not formally exist, no matter how large n is. However, Leshno and
Levy (2002) show that as n increases the CDF of X shifts right faster than the CDF
of Y , and that nearly all utility functions will prefer X(n) to Y (n) for large n. The
concepts of AFSD and ASSD are definitely applicable to CEA.
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Assessing First-Order Stochastic Dominance with Statistical Uncertainty
As before, we use a generic two-sample set up to describe the procedures. Let
{X1, ..., Xn0} be the data from one treatment and {Y1, ..., Yn1} be the data from
a second treatment, and N = n0 + n1. Let Fˆj(x) be the empirical CDF based
on the data, the well-known estimator of the unknown CDF Fj(x), j = 0, 1. Let
Dˆ(x) = Fˆ1(x)− Fˆ0(x). With the data being estimated, methods are needed to infer
from the sample whether FSD exists in the population.
One possibility is using methods to construct a confidence region for D(x) =
F1(x)−F0(x) and using this to assess FSD. Since D(x) is a function, the confidence
region has to be valid for all (or most) values of x, i.e., a simultaneous confidence
region. Perhaps the simplest method to construct such a confidence region is through
the use of the two-sample Kolmogorov-Smirnov (KS) statistic or its weighted ver-
sions. We will consider first the unweighted KS statistic. Let
(4.19) K = sup
−∞<x<∞
|Dˆ(x)−D(x)| = sup
−∞<x<∞
|(Fˆ1(x)− F1(x))− (Fˆ0(x)− F0(x))|.
It is well known that the distribution of K under the null hypothesis that F1(x) =
F0(x) (and the distribution is continuous) is distribution-free, i.e., it does not depend
on the underlying distribution. This is true even in finite samples. The null distri-
bution of K has been well studied and is available in most software packages. Let
Kα = Kα(n0, n1) be the (1 − α)−th quantile of the distribution of K with sample
sizes n0 and n1. From this and equation 4.19 above, we have
(4.20) P
(
sup
−∞<x<∞
|Dˆ(x)−D(x)| < Kα
)
≥ 1− α.
In other words,
(4.21) Dˆ(x)±Kα
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is a two-sided confidence region for D(x) for all x – i.e., it is a simultaneous confidence
region. We can now use this band to assess FSD as follows. If the upper bound of
this region is below zero for all x, we can conclude that D(x) ≤ 0 for all x even
after taking the statistical uncertainty into account. This implies that F1 1 F0.
Conversely, if the lower bound is strictly above zero, it implies that F0 1 F1.
The two-sided confidence region treats F1 and F0 symmetrically. In CEA, treat-
ment 1 is new and we may be interested only in assessing if F1 1 F0 or not. In that
case, we can just construct a one-sided upper bound for the confidence region. If the
upper bound is below zero for all x, we conclude that F1 1 F0.
One disadvantage of the K−band above is that the width of the band ±Kα is
constant for all x. This is not desirable as the variance of Dˆ(x) tends to zero in both
the lower and upper tails and is highest in the middle regions. To account for this,
we can use a weighted version of the K− statistic of the form
(4.22) W = sup
{x:a<x<b}
|Dˆ(x)−D(x)|/ŜE(Dˆ(x)).
Recall that
SE(Dˆ(x)) =
√
F1(x)(1− F1(x))/n1 + F0(x)(1− F0(x))/n0,
which can be estimated by plugging in the corresponding empirical CDF’s. The
range of the statistic W has to be restricted to {a < x < b} as the variance tends to
zero in the lower and upper tails and dividing by the standard deviation can blow
up the value of the statistic in the tails. In practice, one can take a and b to the
lower and upper percentiles of the data, corresponding to some level such as .01 or
.05. With this choice, the distribution of the statistic is also distribution-free under
the null-hypothesis. Using this test statistic, we get the following band, sometimes
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called the W-band (Doksum and Sievers, 1976):
(4.23) Dˆ(x)±Wα
√
Fˆ1(x)(1− Fˆ1(x))/n1 + Fˆ0(x)(1− Fˆ0(x))/n0.
Note that the width of this band decreases as one moves to the tails, and it will be
smaller in the lower and upper tails compared to the K-band.
We use a new example to demonstrate the use of these bands for FSD, and continue
this example into the discussion of SSD also. The data are given in Appendix 4.6.2;
as with the previous example, we suppose that the data has been observed at 32
points for each of the treatments. Figure (4.14) shows the empirical distribution
functions of the monetary benefit for treatments 1 and 0 in our illustrative example;
the distributions do not cross, so we cannot rule out FSD. Figure (4.15) shows the
two-sided confidence band for the monetary benefit, using both the weighted and
unweighted statistics. It shows that the K-band has constant width while the W-
band is narrower in the tails. In both cases, the upper band is not completely below
zero, so we cannot conclude that F1 1 F0. For the true distributions, shown in
Appendix 4.6.2, we do have FSD but the statistical uncertainty from estimating the
distributions masks this. If the dominance is stronger or if the sample size is much
larger, we would have been able to determine the truth.
Assessing Second-Order Stochastic Dominance with Statistical Uncertainty
There has been less attention in the statistical literature on assessing SSD from
sample data, but some work has been done in economics (see McFadden (1989);
Barrett and Donald (2003)). Also, the problem is more complex as the corresponding
K and W statistics are no longer distribution-free; i.e., the distributions of the test
statistics depend on the underlying distribution even if F1 = F0. One would have to
compute the distribution for each case separately, but the distributions are unknown,
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Figure 4.14: Empirical Cumulative Distribution Function.
making the problem difficult analytically. However, resampling methods can be used
to solve this problems.
As in the FSD case, we use a generic two-sample set up to describe the procedures.
Let {X1, ..., Xn0} be the data from one treatment and {Y1, ..., Yn1} be the data from
a second treatment, and N = n0 + n1. Let Gˆj(x) be the empirical estimator of the
unknown Gj(x) =
∫ x
−∞(F1(y)− F0(y))dy, j = 0, 1. Let Lˆ(x) = Gˆ1(x)− Gˆ0(x).
We start with a discussion of methods for constructing a simultaneous confidence
region for L(x) = G1(x) − G0(x), As with the FSD case, we use weighted and
unweighted statistics. Let
(4.24) M = sup
−∞<x<∞
|Lˆ(x)| = sup
−∞<x<∞
|(Gˆ1(x)− Gˆ0(x))|.
As we have noted, the distribution of M depends on the common (but unknown)
distribution under the null hypothesis that F1(x) = F0(x). As discussed in Barrett
and Donald (2003), we will use bootstrap techniques. Specifically, a large number
of bootstrap replications of Fˆ1(x) and Fˆ0(x) are created. Denoting them as Fˆ
∗
1 (x)
and Fˆ ∗0 (x), we compute Gˆ
∗
1(x) and Gˆ
∗
0(x) and M
∗ = sup−∞<x<∞ |(Gˆ∗1(x) − Gˆ∗0(x))|.
128
Figure 4.15: Left: Dˆ(x) and K− band. Right: Dˆ(x) and W− band.
Let M∗α be the (1− α)−th quantile of the distribution of M∗. Using this we get the
unweighted two-sided band as
(4.25) Lˆ(x)±M∗α.
We also consider an analogous weighted statistic, as in the FSD case:
(4.26) U = sup
{x:a<x<b}
|Lˆ(x)− L(x)|/ŜE(Lˆ(x)),
which leads to the weighted confidence band:
(4.27) Lˆ(x)± UαŜE(Lˆ(x)).
Again the critical value will Uα will have to be obtained via bootstrap. But there
is an additional complication here in that ŜE(Lˆ(x)) can be computed only after all
the bootstrap samples are available, while it is needed for each bootstrap computa-
tion. Similar problems have been handled by the double-bootstrap in the statistical
literature Efron and Tibshirani (1993). This involves running another bootstrap
within each bootstrap computation to estimate ŜE(Lˆ(x)) and then computing the
weighted statistic.
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The left and right panels of Figure (4.16) show the M− or U− bands. Neither one
provides support for SSD of F1 over F0. The bands are rather wide, indicating the
large variability of the estimated Gˆj’s. The main conclusion to be made here is that
establishing SSD in the presence of statistical uncertainty is difficult and requires
very large sample size.
Figure 4.16: Left: M− band for Assessing SSD. Right : U− band for Assessing SSD.
4.5 Conclusion
We have reviewed metrics for quantifying treatment effect in CEA and methods
for making comparisons in the presence of statistical uncertainty. We have tried to
make a case for going beyond mean-based analysis to examine the entire distributions
and using concepts of stochastic dominance. We also discussed comparisons based
on utility functions. Because the utility functions of decision-makers are largely
unknown, we propose sensitivity analysis about the parameters of the utility function.
The procedures we examined for determining SSD in the presence of estimation
uncertainty have very low power, and additional research on alternative methods is
needed.
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4.6 Appendix
4.6.1 Illustrative Data
This appendix contains the data used for the examples about statistical infer-
ence (except for stochastic dominance) in this paper. Assume the true underlying
distribution of (E0, C0) ∼ LN

 0.3
7.2
 ,
 0.4, 1
1, 7.3

. Likewise, assume the true
underlying distribution of
(E1, C1) ∼ LN

 0.8
7.2
 ,
 0.25, 1
1, 7

. Only n0 = n1 = 32 samples are avail-
able from each population. The summary statistics for these samples are given in
Table 4.2.
Table 4.2: Illustrative Example Summary Statistics
Treatment µˆ(E) µˆ(C) v(E) v(C) cv
0 1.30 17,916 0.017 182,592,614 1400
1 3.09 3,180 0.124 1,301,030,431 7879
The full sample data is in Table 4.3.
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Table 4.3: Illustrative Example Data
Sample E0 C0 E1 C1
1 0.92 163 3.05 41628
2 1.03 496 0.92 10
3 1.47 24715 4.93 19870
4 1.22 8164 2.21 6387
5 1.22 197 2.76 6028
6 0.83 84 1.59 3001
7 0.89 24 1.17 108
8 0.54 25 3.17 13130
9 1.65 12264 1.17 21
10 1.76 9049 1.52 3499
11 0.85 222 0.83 666
12 1.07 1088 1.06 11
13 1.13 222 1.52 92
14 1.14 8748 7.82 344820
15 0.63 1 2.59 256
16 1.46 6774 3.75 39273
17 2.44 29236 1.57 395
18 1.06 400 1.29 38
19 1.96 1415 2.43 6013
20 1.48 7731 3.06 22258
21 0.59 96 7.32 1103670
22 1.33 1013 3.93 22566
23 1.91 535 3.20 110
24 4.37 434992 7.83 271106
25 2.04 13612 1.14 215
26 1.34 4718 5.01 29924
27 0.68 142 1.34 164
28 0.74 165 3.13 25471
29 1.45 4878 2.84 2170
30 0.83 1197 5.20 14646
31 0.75 475 4.36 13537
32 0.94 474 5.00 30678
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4.6.2 Stochastic Dominance Section Illustrative Data
This appendix contains the data used to demonstrate the use of confidence bands
for FSD and SSD. Assume the true underlying distribution of
(E0, C0) ∼ LN

 0.3
7.2
 ,
 0.25, 1
1, 7.

. Likewise, assume the true underlying
distribution of (E1, C1) ∼ LN

 0.8
7.2
 ,
 0.25, 1
1, 7

. Only n0 = n1 = 32 sam-
ples are available from each population. The true distribution functions of these
distributions are shown in Figure 4.17. It is clear from this that there is FSD at a
population level, but the work in this paper shows that the uncertainty is too high
to conclude there is FSD in the case of the 32-patient samples.
Figure 4.17: True Distribution of Stochastic Dominance Illustrative Data.
Table 4.4 contains the sample data used for the stochastic dominance examples.
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Table 4.4: SSD Illustrative Example Data
Sample E0 C0 E1 C1
1 1.01 38 1.29 498
2 1.19 8780 0.99 15
3 2.69 22391 1.55 727
4 0.67 114 2.45 3681
5 0.78 7 2.49 63999
6 3.14 20697 2.08 53816
7 0.69 53 1.56 2219
8 1.36 28034 1.56 118
9 2.27 12041 2.61 340
10 0.65 51 2.19 127
11 1.46 3280 2.39 4480
12 1.06 10 6.42 18387
13 0.63 13 3.45 12200
14 0.77 893 4.76 101872
15 0.96 272 1.52 111
16 2.88 71579 2.43 7133
17 1.32 6786 4.67 3982
18 2.11 286 1.20 57
19 0.56 26 2.88 1131
20 1.06 3009 1.05 19
21 0.79 158 1.87 139
22 0.26 1 1.02 3
23 2.68 112409 2.07 245
24 1.40 77431 2.55 317
25 1.33 5469 0.91 13
26 0.75 256 2.65 815
27 0.93 349 2.28 2604
28 0.94 191 1.49 1269
29 1.49 2730 2.21 3748
30 0.87 111 0.87 105
31 0.66 141 1.04 24
32 1.85 5711 2.10 510
CHAPTER V
Conclusion and Future Work
5.1 Summary and Contributions
Cost-effectiveness analysis will increase in importance as healthcare becomes more
expensive and resources become more constrained. CEA is interdisciplinary, draw-
ing on knowledge from medical doctors and epidemiologists, and increasingly from
statisticians and operations research professionals. This thesis contributes to the
CEA literature by developing methods of evaluation and analysis of cost-effectiveness
data. The following are key components of the contribution.
1. Expressions were developed to evaluate stationary, progressive multi-state mod-
els of disease used for CEA. With the assumption of independence between
transition and sojourn distributions, as is made in the case of Markov and
semi-Markov models common in the literature, the expressions can be easily
evaluated analytically. In the case of non-stationary processes, which have a
dependence between transitions, the expressions can still be evaluated through
a straightforward simulation. This approach has the advantage over traditional
DES of evaluating and weighting all possible patient paths, similar to stratified
sampling in population studies.
2. The stochastic process underlying the analysis of disease progression was made
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explicit in Chapter III. We demonstrated the usefulness of using graphical
methods to analyze the simulation data more extensively and to develop key
insights into the performance of treatments.
3. A review of CEA metrics and methods for incorporating statistical uncertainty
was presented, including a clarification of confusion in the CEA literature re-
garding the use of large-sample theory in determining confidence intervals. We
also proposed the use of rank-based methods in CEA, and discussed the deter-
mination of uncertainty in the case of censoring. We expanded the discussion
of CEA to comparisons of entire distributions of rewards. We proposed two
methods for evaluating these distributions: explicit analysis using utility func-
tions and first- and second-order stochastic dominance, for the cases when the
decision-maker utility function is unknown. New contributions to the CEA liter-
ature in this chapter include stochastic dominance comparisons in the presence
of estimation uncertainty, use of rank methods, and analysis with censored data.
5.2 Limitations and Future Research
There are several directions for future research related to this dissertation. The
main limitation of this research is that the examples used in all three papers are
illustrative, and are not based on actual clinical data. This suits the purposes of
methodology development well, but the ideas here should be applied and proved
using actual data, and the availability of such data can be limited. In particular,
the methods Chapter IV should be applied alongside the design and execution of a
clinical or observational trial, and an original simulation study should be conducted
using the methods in Chapter II and III.
Additionally, here are several comments, specific to each of the papers, about
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opportunities for future research.
The expressions in Chapter II are limited to the case of progressive models of
disease. While in general, many CEA models are progressive or can be designed that
way, many existing models are not progressive, and analysts will continue to cre-
ate non-progressive models. The development of methods to handle non-progressive
models is a challenging problem; existing expressions for mean rewards in the rewards
literature are recursive (Howard, 1971; Janssen and Manca, 2006), due to the infinite
number of paths through a non-progressive multi-state model. These recursive cal-
culations are tedious in many cases, and not adopted to CEA. The development of
algorithms and non-DES simulation methods specific to CEA of more general (non-
progressive) evaluation of random and expected rewards would be of use to the CEA
field, and novel in the CEA literature.
The analysis in Chapter III, while useful, is more time-consuming and requires
more knowledge of statistical software than many of the end-users of the information,
and even the analysts who create simulation models, may have. The development
of software to conduct the analysis, including plotting densities and quantiles, and
stratifying on covariates, would be an advancement in the use of this analysis. We
created prototype software as a proof-of-concept, but significantly more information
about end-user requirements and computer science knowledge is needed to create
such software. It would also be interesting to use existing simulation data and apply
the graphical techniques in the paper to see which prove the most useful across
many studies, and from that develop a recommended order of analysis, or even a
prescriptive decision-tree directing analysis for those less familiar with analyzing
data.
For the research presented in Chapter IV, further work is needed in assessing
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stochastic dominance under uncertainty. This dissertation used only KS-type statis-
tics, and these often have limited power, which was obvious in the very wide confi-
dence limits, particulary for second-order stochastic dominance. Particularly chal-
lenging is the fact that it would be desirable to develop statistical tests for dominance
in which the null hypothesis is non-dominance and the alternative is dominance; this
makes it difficult to use many of the L2 tests standard in the literature, where L2
tests are based on measures of the squared integrated distance between the empirical
CDFs (for instance, Cramer-von Mises and Anderson-Darling tests).
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